{"docstore/metadata": {"bfc8d877-35fe-44fc-8eef-eb400919f219": {"doc_hash": "16b2301baecdba8fc6fe57b2a29cb4d8bd9f8e4ee04539fbfdb0fbb2d8aa6437"}, "672a39ab-7a7b-4663-acfc-5275cf133ba1": {"doc_hash": "d581863108ada8e2c73f5345f5664510f297c7b2e666adaaa40fd62cfedb5302"}, "06d85b90-bd53-462a-a8e3-d8178e418217": {"doc_hash": "bd6927eb504ba0d1974ddf9067a5976bd815f812964a36e7da1ea427bbaf97b0"}, "bf3c95e5-c8a7-4512-a7f6-f49242c241b9": {"doc_hash": "879863abbb34c1c87ba474b0c98917263ff26aba381fae93194e430e7d6810ef"}, "0db985ec-628a-488b-8fb9-661208994002": {"doc_hash": "c863dcd7369790d8660ecdd978f963ba539224f6c7aa452e706c81787e834d70"}, "609f90f6-301f-406c-981c-d012a6b828f2": {"doc_hash": "b280bf91df9c7263656eae9821e212b957d4730c4bec6b0c27b4ae37a48d5442"}, "7beec391-5b20-4fb3-9abc-41419b5d295f": {"doc_hash": "719c55fc235e5488495b3dc958f4d4967a3f00aceaa3d35172d76b62eb674516"}, "f8637173-d655-4302-99f4-08a15b391843": {"doc_hash": "f0a3460ccb81ec4f55580fe2c2930ca41d911d7cd2c109f6680131ff8fa2b1b2"}, "04550f71-d7cc-499f-80ba-93ab50274415": {"doc_hash": "f6046fc59459f36c0e677d780a467663a81f7ce000c1466544942b67e365c07a"}, "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a": {"doc_hash": "77ef7725da711affe7301ef3f3212d4593895828b4fab70af748c9520bb47c0e"}, "06d9a118-1636-480d-b21d-3ee904356b85": {"doc_hash": "11955eaf648c2510b85ed6f45650b1af54bf603be61697288c216e99c52dfbed"}, "2f39b3a8-7107-4bbf-a70a-806d8262427b": {"doc_hash": "022adb97d98b347e5cd4058af29dd16840a1780652f9ebf8331fe6d023663393", "ref_doc_id": "bfc8d877-35fe-44fc-8eef-eb400919f219"}, "422a4fa0-f439-44d3-b69f-7605a774538e": {"doc_hash": "94fea5a2ed83d5530d359746707768e114056bdcaa192231f3acc60a33941572", "ref_doc_id": "bfc8d877-35fe-44fc-8eef-eb400919f219"}, "6e108435-e3a2-45db-9cac-40fde64aee65": {"doc_hash": "7204f535ced274c1567bf0288ac324f3df6566de7796b52de14a3d980074e8a0", "ref_doc_id": "bfc8d877-35fe-44fc-8eef-eb400919f219"}, "a1ddabdd-d2ee-4d53-b0b8-08963da293bb": {"doc_hash": "6e561a73fce2a606672526b7d3e9ee4b7242962038794969140506f93bd45932", "ref_doc_id": "bfc8d877-35fe-44fc-8eef-eb400919f219"}, "ff9c8508-0b28-4ab0-8f5a-f8e7f349c8e1": {"doc_hash": "cc2af94f9030ea44c3e6817802f35b8da15349851cc68bfc52c892dc136e2fef", "ref_doc_id": "bfc8d877-35fe-44fc-8eef-eb400919f219"}, "fa5c19bf-fc62-4fb2-a295-8e97b2140023": {"doc_hash": "a423ff485828056cb17aac489c59c075fa4b55943121f96fa7344c71357bd169", "ref_doc_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1"}, "40223ddf-cd72-4d04-80e9-313875f9246e": {"doc_hash": "073922d47c36123bf6184a645d27aef252b041c53869c3a66704d0eee0c8df47", "ref_doc_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1"}, "183b296c-ed4d-4070-8252-25568fbc2eae": {"doc_hash": "4f735f9628eb9288fdaaeb5a06846eedbf2b5f43a6bce7341575b598cf4a3583", "ref_doc_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1"}, "f71fe3d0-a17e-420f-830a-5501ace567b3": {"doc_hash": "06056e519ef079224f233d3fe0b2134fb6fa7c96d46b5eb03b1e707b27ca29f8", "ref_doc_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1"}, "87029fc9-73d8-4fd0-93a4-c84944fba0c9": {"doc_hash": "575dcb39c133adaa5614cf6f2d719d0f03d9d96db65f94311fc50917802aafaa", "ref_doc_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1"}, "d7a5ac4b-9026-4335-bf63-1f522999e1d6": {"doc_hash": "484c137b814f5efce041adfebd56b5892ed889e1243129d6d94eb9d9787a5dbb", "ref_doc_id": "06d85b90-bd53-462a-a8e3-d8178e418217"}, "0c506829-03c3-4e6f-b38a-0d1e52127ff2": {"doc_hash": "e8ff6fcc69f53dcb4f64e4f8bd5d8a55575b32353b7ebc39628352a6fd0909d2", "ref_doc_id": "06d85b90-bd53-462a-a8e3-d8178e418217"}, "8716d68a-85f5-4cea-a2bf-c866d40291fb": {"doc_hash": "c7bf4728401b7fbe0185ccdba6df1962b6940a608b6645f416563e102308ddbd", "ref_doc_id": "06d85b90-bd53-462a-a8e3-d8178e418217"}, "f96b4c1c-1a97-4e92-b582-082ea78bdaba": {"doc_hash": "ab983b85e0078eecb6bd72a6ec59a0ecb803127f0db40042a2a0245f6f412af9", "ref_doc_id": "06d85b90-bd53-462a-a8e3-d8178e418217"}, "e753db88-bc85-46f5-9f8d-1029109515e5": {"doc_hash": "dcce44f2801e1a8af2eb952fae99b6dbcd5fda17b470a7fe83b8e10033471d45", "ref_doc_id": "06d85b90-bd53-462a-a8e3-d8178e418217"}, "9e508ff4-a59a-4527-b3f0-c57ab152f418": {"doc_hash": "07a7c0e69ce2cf92b23500d57f4f1c79019f77903dd586a10ea924a035020b00", "ref_doc_id": "06d85b90-bd53-462a-a8e3-d8178e418217"}, "a38d1522-b9c0-4b43-87ec-a72cc00f6784": {"doc_hash": "73f58bb02a6f5c9d4c9aa6c1da21ee2738f67a2826ab75a7c236a5404adbe297", "ref_doc_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9"}, "d92ca9cf-dfef-45e0-940e-ca3bd23ad6d9": {"doc_hash": "9c2238d9f5f3596bbcc7de383afd166e67b5d09fed247f6a1ed10728d1cc6088", "ref_doc_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9"}, "c677c62b-7286-4c54-bb71-fcdbdb60e215": {"doc_hash": "f50f6944ce6af678369012dd54635a7e6fe9decd67ca5de5d6001bbc198d3349", "ref_doc_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9"}, "937ff68d-1aa4-46a3-a630-9a2eefdf0784": {"doc_hash": "989e68e099c98b7ec56c900f9080a08bd0eca492fb8ca82e21cc29ede712fcfe", "ref_doc_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9"}, "cfb884ef-e5c0-48e9-b011-4b40eacd5d32": {"doc_hash": "b2083e090f1e0ff10de726f4703eb8dcf2ca3f2c81fd1ae5d45838d3ac7d4462", "ref_doc_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9"}, "6216f214-1228-4ee3-8cbe-12685d7d54f0": {"doc_hash": "769f918e6fa6c096ee6261f0dff532eb7f42183840a6c655fce01134ee1725d4", "ref_doc_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9"}, "927c24b9-a4be-4434-9fcd-ce85f082d353": {"doc_hash": "c863dcd7369790d8660ecdd978f963ba539224f6c7aa452e706c81787e834d70", "ref_doc_id": "0db985ec-628a-488b-8fb9-661208994002"}, "05925efc-e111-4144-ba67-997207668dff": {"doc_hash": "7c851aad6f4450f8f0eae10f7093bb8f801a9da924ac16fadde1d15e5519ce7b", "ref_doc_id": "609f90f6-301f-406c-981c-d012a6b828f2"}, "cb226240-ce85-4610-9086-342a37977f38": {"doc_hash": "fb562f445ad09739f34644f642a5713069768149e7c71a734e26d3a8b79bb364", "ref_doc_id": "609f90f6-301f-406c-981c-d012a6b828f2"}, "7faa8a9f-e98b-4db7-bfe5-e8ac416c6810": {"doc_hash": "d95c6135f02acb04584d3f92a6bf42f84a3271a76f7e2cf68e3126732ea874c4", "ref_doc_id": "609f90f6-301f-406c-981c-d012a6b828f2"}, "e0aaac66-3403-4944-b48c-6a36ed80f016": {"doc_hash": "53fa052d583ac1b21c6130fdeffcbba3f5fa4e2b44aa8f01d7cfedcbee5bf051", "ref_doc_id": "609f90f6-301f-406c-981c-d012a6b828f2"}, "ed7f2783-2b31-48ad-9c5c-33816b54fd1c": {"doc_hash": "6eb9981fac3d55790cef36bcb5e4927dc62e903fca7b11beafdb44c522081ea8", "ref_doc_id": "609f90f6-301f-406c-981c-d012a6b828f2"}, "4baef134-5231-4b7d-b791-c9a9196988c9": {"doc_hash": "719c55fc235e5488495b3dc958f4d4967a3f00aceaa3d35172d76b62eb674516", "ref_doc_id": "7beec391-5b20-4fb3-9abc-41419b5d295f"}, "376f39d4-26b9-4d04-b712-4aefcef2eb04": {"doc_hash": "55f5b05bbf6aac6b825c02f64eb7d8b45bf52a3bb85e72f40a05df77f0722c9e", "ref_doc_id": "f8637173-d655-4302-99f4-08a15b391843"}, "66ea171e-5d2b-4eea-86df-6d8d4bac46e6": {"doc_hash": "657809032ee32fa4d9730bafb4afaaa0bb26e91e5b95bc57763257f30c9cad96", "ref_doc_id": "f8637173-d655-4302-99f4-08a15b391843"}, "76bfb191-ba8e-42d9-ae10-882c82d52fe3": {"doc_hash": "e78e5368365c241deb8ec59a92b676bfb8740b495ef7fa6245055f7f8177c293", "ref_doc_id": "f8637173-d655-4302-99f4-08a15b391843"}, "96bb9068-a533-4f57-944e-789e4f86ccbf": {"doc_hash": "a8a19defc2b3786f7ef18a762b13ee8b3c227c2f4e012dcd40ec16a9ddd022ef", "ref_doc_id": "04550f71-d7cc-499f-80ba-93ab50274415"}, "05d3d67a-dc2e-4244-8ba8-a085e580a36a": {"doc_hash": "3db9f95a9c1f35ab857b52817ba23e0df10431d388aa935876b9a7e458c12195", "ref_doc_id": "04550f71-d7cc-499f-80ba-93ab50274415"}, "4225121b-5670-4f9d-ba79-8cabaab22aae": {"doc_hash": "3422c77f665acdc479f8cf9542cf57da2d47845113e64dee0de32293fc6f37f8", "ref_doc_id": "04550f71-d7cc-499f-80ba-93ab50274415"}, "fa439f02-2fb8-4cde-9f3a-925915c77764": {"doc_hash": "e48a2e9a2b34fd222f14e7cdd91407cb808997d44a299144b94eddc1fe50bfba", "ref_doc_id": "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a"}, "9f2fd2c9-1cf0-402c-8d06-05fe6d436770": {"doc_hash": "a94cabdbed902ec08d63ef98e8e80e6f33540f1d30252bdfce63377039eec437", "ref_doc_id": "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a"}, "5ca96715-541d-475a-961e-1c769e48cf70": {"doc_hash": "1e5d10ef4fdf148c483c98b7ddb9010466da0e523d0507dfa3133ae84c2a4ab3", "ref_doc_id": "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a"}, "93abe397-b96e-4846-bc48-5c242f3a8ce0": {"doc_hash": "bc8731e4f6bc26dbd97158927e14ac8f06e92c2691dfa496c82cf81144f89842", "ref_doc_id": "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a"}, "1ab98b7d-a216-4fbb-83f3-87448af1fabd": {"doc_hash": "25a632aaa5af8e8c1991e7e286491807bbd5eac07ccbfd3570997bc69c8f3f39", "ref_doc_id": "06d9a118-1636-480d-b21d-3ee904356b85"}, "0bd9101c-408e-4dfc-b6b5-e00afa197afc": {"doc_hash": "6a0b13c33785f11a7362cbb992c0953e942a416db5f67ef367d6a5e84da4b8b0", "ref_doc_id": "06d9a118-1636-480d-b21d-3ee904356b85"}, "22052704-67af-4bad-9e7e-691830cbce6e": {"doc_hash": "2292459543e50e8864e249ce15eb57a356ee8ec08a2a8fe99cd7d590af0a979b", "ref_doc_id": "06d9a118-1636-480d-b21d-3ee904356b85"}, "85453251-171a-4b92-9525-90761c071881": {"doc_hash": "30f5706dbafb2d97ed6946a4ca32b7e9de28489ef3c28d0a4365b50c913cf213", "ref_doc_id": "06d9a118-1636-480d-b21d-3ee904356b85"}, "fc49b8da-9c07-44e8-8990-3e0258691387": {"doc_hash": "55dc366f38ef64df429b33b12ca51bf72aea6c5001bf5208d40b5b124040f73e", "ref_doc_id": "06d9a118-1636-480d-b21d-3ee904356b85"}, "6ce9a047-d444-4362-9486-37cb9d3aeb7e": {"doc_hash": "df9651b63c3a4c675934d96933dfb3df0db7dc49908c6ab6f00355a07f888be8", "ref_doc_id": "06d9a118-1636-480d-b21d-3ee904356b85"}, "33bb6070-7027-4e5e-b95e-555b18ee5bda": {"doc_hash": "e3e832c1b604f18ce2ea8f453699ac7050066df015578ad32ef1ee880e1715b5", "ref_doc_id": "06d9a118-1636-480d-b21d-3ee904356b85"}}, "docstore/data": {"2f39b3a8-7107-4bbf-a70a-806d8262427b": {"__data__": {"id_": "2f39b3a8-7107-4bbf-a70a-806d8262427b", "embedding": null, "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfc8d877-35fe-44fc-8eef-eb400919f219", "node_type": "4", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "16b2301baecdba8fc6fe57b2a29cb4d8bd9f8e4ee04539fbfdb0fbb2d8aa6437", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "422a4fa0-f439-44d3-b69f-7605a774538e", "node_type": "1", "metadata": {}, "hash": "1214f6a72c12b8f82bfd4207440e8501abd222d7a193e215bee3c93962d83342", "class_name": "RelatedNodeInfo"}}, "text": "A Multi-Center Randomised Controlled Trial of\nGatifloxacin versus Azithromycin for the Treatment of\nUncomplicated Typhoid Fever in Children and Adults in\nVietnam\nChristiane Dolecek1,5,6*, Tran Thi Phi La3, Nguyen Ngoc Rang3, Le Thi Phuong4, Ha Vinh2, Phung Quoc\nTuan1, Doan Cong Du3, Nguyen Thi Be Bay3, Duong Thanh Long3, Luong Bich Ha3, Nguyen Trung Binh3,\nNguyen Thi Anh Hong3, Pham Ngoc Dung3, Mai Ngoc Lanh4, Phan Van Be Bay4, Vo Anh Ho4, Nguyen\nVan Minh Hoang2, Tran Thu Thi Nga1,2, Tran Thuy Chau2, Constance Schultsz1,5, Sarah J. Dunstan1,5,\nKasia Stepniewska1,5, James Ian Campbell1,5, To Song Diep2, Buddha Basnyat7, Nguyen Van Vinh Chau2,\nNguyen Van Sach3, Nguyen Tran Chinh2, Tran Tinh Hien2, Jeremy Farrar1,5,6\n1Oxford University Clinical Research Unit, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, 2The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam,\n3An Giang Provincial Hospital, Long Xuyen, Vietnam, 4Dong Thap Provincial Hospital, Cao Lanh, Dong Thap, Vietnam, 5Nuffield Department of Clinical Medicine, John\nRadcliffe Hospital, Oxford, United Kingdom, 6The London School of Hygiene and Tropical Medicine, London School of Hygiene and Tropical Medicine, London,", "start_char_idx": 0, "end_char_idx": 1208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "422a4fa0-f439-44d3-b69f-7605a774538e": {"__data__": {"id_": "422a4fa0-f439-44d3-b69f-7605a774538e", "embedding": null, "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfc8d877-35fe-44fc-8eef-eb400919f219", "node_type": "4", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "16b2301baecdba8fc6fe57b2a29cb4d8bd9f8e4ee04539fbfdb0fbb2d8aa6437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f39b3a8-7107-4bbf-a70a-806d8262427b", "node_type": "1", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "022adb97d98b347e5cd4058af29dd16840a1780652f9ebf8331fe6d023663393", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e108435-e3a2-45db-9cac-40fde64aee65", "node_type": "1", "metadata": {}, "hash": "24136236a92648ae7cbd20ceeb0f0252f9c546b663b8841c50a462476253825c", "class_name": "RelatedNodeInfo"}}, "text": "Dong Thap, Vietnam, 5Nuffield Department of Clinical Medicine, John\nRadcliffe Hospital, Oxford, United Kingdom, 6The London School of Hygiene and Tropical Medicine, London School of Hygiene and Tropical Medicine, London, United\nKingdom, 7Patan Hospital, Lagankhel, Lalitpur, Nepal\nAbstract\nBackground: Drug resistant typhoid fever is a major clinical problem globally. Many of the first line antibiotics, including the\nolder generation fluoroquinolones, ciprofloxacin and ofloxacin, are failing.\nObjectives: We performed a randomised controlled trial to compare the efficacy and safety of gatifloxacin (10 mg/kg/day)\nversus azithromycin (20 mg/kg/day) as a once daily oral dose for 7 days for the treatment of uncomplicated typhoid fever inchildren and adults in Vietnam.\nMethods: An open-label multi-centre randomised trial with pre-specified per protocol analysis and intention to treat analysis\nwas conducted. The primary outcome was fever clearance time, the secondary outcome was overall treatment failure (clinicalor microbiological failure, development of typhoid fever-related complications, relapse or faecal carriage of S. typhi).\nPrincipal Findings: We enrolled 358 children and adults with suspected typhoid fever. There was no death in the study. 287\npatients had blood culture confirmed typhoid fever, 145 patients received gatifloxacin and 142 patients received\nazithromycin.", "start_char_idx": 988, "end_char_idx": 2378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e108435-e3a2-45db-9cac-40fde64aee65": {"__data__": {"id_": "6e108435-e3a2-45db-9cac-40fde64aee65", "embedding": null, "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfc8d877-35fe-44fc-8eef-eb400919f219", "node_type": "4", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "16b2301baecdba8fc6fe57b2a29cb4d8bd9f8e4ee04539fbfdb0fbb2d8aa6437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "422a4fa0-f439-44d3-b69f-7605a774538e", "node_type": "1", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "94fea5a2ed83d5530d359746707768e114056bdcaa192231f3acc60a33941572", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1ddabdd-d2ee-4d53-b0b8-08963da293bb", "node_type": "1", "metadata": {}, "hash": "1096ded6d33990e28fec8aeab7dea821da498e4056a9866cf39ae0e3d834e030", "class_name": "RelatedNodeInfo"}}, "text": "There was no death in the study. 287\npatients had blood culture confirmed typhoid fever, 145 patients received gatifloxacin and 142 patients received\nazithromycin. The median FCT was 106 hours in both treatment arms (95% Confidence Interval [CI]; 94\u2013118 hours for\ngatifloxacin versus 88\u2013112 hours for azithromycin), (logrank test p= 0.984, HR [95% CI] = 1.0 [0.80\u20131.26]). Overall treatment\nfailure occurred in 13/145 (9%) patients in the gatifloxacin group and 13/140 (9.3%) patients in the azithromycin group,\n(logrank test p= 0.854, HR [95% CI] = 0.93 [0.43\u20132.0]). 96% (254/263) of the Salmonella enterica serovar Typhi isolates were\nresistant to nalidixic acid and 58% (153/263) were multidrug resistant.\nConclusions: Both antibiotics showed an excellent efficacy and safety profile. Both gatifloxacin and azithromycin can be\nrecommended for the treatment of typhoid fever particularly in regions with high rates of multidrug and nalidixic acid resistance.The cost of a 7-day treatment course of gatifloxacin is appr oximately one third of the cost of azithromycin in Vietnam.\nTrial Registration: Controlled-Trials.com ISRCTN67946944\nCitation: Dolecek C, Phi La TT, Rang NN, Phuong LT, Vinh H, et al.", "start_char_idx": 2215, "end_char_idx": 3418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1ddabdd-d2ee-4d53-b0b8-08963da293bb": {"__data__": {"id_": "a1ddabdd-d2ee-4d53-b0b8-08963da293bb", "embedding": null, "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfc8d877-35fe-44fc-8eef-eb400919f219", "node_type": "4", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "16b2301baecdba8fc6fe57b2a29cb4d8bd9f8e4ee04539fbfdb0fbb2d8aa6437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e108435-e3a2-45db-9cac-40fde64aee65", "node_type": "1", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "7204f535ced274c1567bf0288ac324f3df6566de7796b52de14a3d980074e8a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff9c8508-0b28-4ab0-8f5a-f8e7f349c8e1", "node_type": "1", "metadata": {}, "hash": "c9d7528e0f2b69ad4d0c390bf03405f367acd513126e1387845100df247d287c", "class_name": "RelatedNodeInfo"}}, "text": "Trial Registration: Controlled-Trials.com ISRCTN67946944\nCitation: Dolecek C, Phi La TT, Rang NN, Phuong LT, Vinh H, et al. (2008) A Multi-Center Randomised Controlled Trial of Gatifloxacin versus Azithromycin for the\nTreatment of Uncomplicated Typhoid Fever in Children and Adults in Vietnam. PLoS ONE 3(5): e2188. doi:10.1371/journal.pone.0002188\nEditor: Robert Frenck, Cincinnati Children\u2019s Hospital Medical Center, United States of America\nReceived July 23, 2007; Accepted March 27, 2008; Published May 21, 2008\nCopyright: /C2232008 Dolecek et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits\nunrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.\nFunding: This study was funded by the Wellcome Trust, UK. The funding source did not play any role in the design, conduct, analysis or publication of the study.\nCompeting Interests: The authors have declared that no competing interests exist.\n* E-mail: cdolecek@oucru.org\nIntroduction\nThere are approximately 21 million cases of typhoid fever\nannually, with more than 210 000 deaths [1]. The emergence ofantimicrobial drug resistance in Salmonella enterica serovar Typhi ( S.\ntyphi) is a major problem particularly in South East Asia and the\nIndian sub-continent and challenges our current treatment options[2\u20134].", "start_char_idx": 3295, "end_char_idx": 4696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff9c8508-0b28-4ab0-8f5a-f8e7f349c8e1": {"__data__": {"id_": "ff9c8508-0b28-4ab0-8f5a-f8e7f349c8e1", "embedding": null, "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfc8d877-35fe-44fc-8eef-eb400919f219", "node_type": "4", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "16b2301baecdba8fc6fe57b2a29cb4d8bd9f8e4ee04539fbfdb0fbb2d8aa6437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1ddabdd-d2ee-4d53-b0b8-08963da293bb", "node_type": "1", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "6e561a73fce2a606672526b7d3e9ee4b7242962038794969140506f93bd45932", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa5c19bf-fc62-4fb2-a295-8e97b2140023", "node_type": "1", "metadata": {}, "hash": "fcdb0b3f724ce1e8e6a36b88120cb117c639cb0d7c719cd7ec95598df70ca5fd", "class_name": "RelatedNodeInfo"}}, "text": "There is a need for an efficacious, safe and affordable oral\nPLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 4697, "end_char_idx": 4824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa5c19bf-fc62-4fb2-a295-8e97b2140023": {"__data__": {"id_": "fa5c19bf-fc62-4fb2-a295-8e97b2140023", "embedding": null, "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "d581863108ada8e2c73f5345f5664510f297c7b2e666adaaa40fd62cfedb5302", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff9c8508-0b28-4ab0-8f5a-f8e7f349c8e1", "node_type": "1", "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "cc2af94f9030ea44c3e6817802f35b8da15349851cc68bfc52c892dc136e2fef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40223ddf-cd72-4d04-80e9-313875f9246e", "node_type": "1", "metadata": {}, "hash": "8c045f63fa011d8639ad68a2c2e10f0df917fbd1c9e99113d3ca50b27f0ba2eb", "class_name": "RelatedNodeInfo"}}, "text": "treatment, particularly in regions with a high proportion of both\nmultidrug and nalidixic acid resistant S. typhi .\nIn Vietnam, multidrug resistant (MDR) isolates of S. typhi\n(resistant to ampicillin, chloramphenicol and trimethoprim-sulfamethoxazol) first appeared in 1993 [5]. From this time thefluoroquinolones became the treatment of choice for typhoid fever\n[4], and were simultaneously sold widely over the counter to treat\nfever of various aetiologies. The extensive antibiotic pressure leadto the selection of single point mutations in the DNA Gyrase A ofS.\ntyphi, causing resistance to nalidixic acid (the prototype quinolone)\nand reduced susceptibility to the fluoroquinolones (but formallythese isolates are still within the Clinical Laboratory StandardInstitute (CLSI) breakpoints for susceptibility) [6]. This resulted ina poor clinical response to treatment with the older generationfluoroquinolones, ofloxacin or ciprofloxacin [7,8].\nThe World Health Organisation recommends the fluoroquin-\nolones or cefixime for the treatment of MDR typhoid fever andazithromycin, the third-generation cephalosporins, or a 10\u201314 daycourse of high-dose older generation fluoroquinolones (e.g.ofloxacin or ciprofloxacin) for the treatment of nalidixic acidresistant typhoid fever [9].\nAzithromycin, an azalid antibiotics, has achieved excellent\nclinical results in the treatment of MDR and nalidixic acid\nresistant typhoid fever [7,8].", "start_char_idx": 0, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40223ddf-cd72-4d04-80e9-313875f9246e": {"__data__": {"id_": "40223ddf-cd72-4d04-80e9-313875f9246e", "embedding": null, "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "d581863108ada8e2c73f5345f5664510f297c7b2e666adaaa40fd62cfedb5302", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa5c19bf-fc62-4fb2-a295-8e97b2140023", "node_type": "1", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "a423ff485828056cb17aac489c59c075fa4b55943121f96fa7344c71357bd169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "183b296c-ed4d-4070-8252-25568fbc2eae", "node_type": "1", "metadata": {}, "hash": "89cf97431ce1722d3a0be7dbc51600932edab6dc9e61905181ac8a732696371c", "class_name": "RelatedNodeInfo"}}, "text": "Azithromycin, an azalid antibiotics, has achieved excellent\nclinical results in the treatment of MDR and nalidixic acid\nresistant typhoid fever [7,8]. However azithromycin is expensive.Cefixime has recently failed in the treatment of nalidixic acidresistant typhoid fever in Nepal (these data were not available atthe start of this trial) [10].\nA recent trial from southern Vietnam used ofloxacin at the\nmaximum recommended dose of 20 mg/kg/day for 7 days for thetreatment of MDR and nalidixic acid resistant typhoid fever and\nshowed high clinical failure rates (36%), high immediate post-\ntreatment faecal carriage (19%), which may lead to transmission inthe community after discharge from hospital, and prolonged meanfever clearance times of 8.2 days (95% CI, 7.2\u20139.2 days) [8].\nThese results underline that the older generation fluoroquino-\nlones are clearly failing in the treatment of nalidixic acid resistanttyphoid fever.\nOf the newer fluoroquinolones, gatifloxacin is available and\naffordable in South and South East Asia including Vietnam [10].Of all the fluoroquinolones, gatifloxacin showed the lowestminimum inhibitory concentrations (MICs) for nalidixic acidresistant S. typhi from Nepal [11] and Vietnam and a rapid\nbactericidal effect in time-kill experiments involving S. typhi isolates\nwith single and double mutations in the GyrA ofS. typhi [6].", "start_char_idx": 1283, "end_char_idx": 2646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "183b296c-ed4d-4070-8252-25568fbc2eae": {"__data__": {"id_": "183b296c-ed4d-4070-8252-25568fbc2eae", "embedding": null, "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "d581863108ada8e2c73f5345f5664510f297c7b2e666adaaa40fd62cfedb5302", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40223ddf-cd72-4d04-80e9-313875f9246e", "node_type": "1", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "073922d47c36123bf6184a645d27aef252b041c53869c3a66704d0eee0c8df47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f71fe3d0-a17e-420f-830a-5501ace567b3", "node_type": "1", "metadata": {}, "hash": "ec846b48d04c578388e76a33750a69d97ed1c4748b5504f4ae783838a03f9db5", "class_name": "RelatedNodeInfo"}}, "text": "typhi [6].\nWe conducted a randomised controlled trial comparing the\nefficacy of gatifloxacin to azithromycin in southern Vietnam, anarea characterised by a very high proportion of MDR (88%) andnalidixic acid resistant (93%) S. typhi isolates [8].\nMethods\nThe protocol for this trial and supporting CONSORT checklist\nare available as supporting information; see Checklist S1 andProtocol S1.\nStudy design and objectives\nThe study was designed as a multicenter, open-label rando-\nmised controlled trial to compare the efficacy and safety ofgatifloxacin versus azithromycin for the treatment of uncompli-cated typhoid fever in children and adult in-patients in southernVietnam.\nThe overall objective of the study was to identify an efficacious,\nsafe, available and affordable oral treatment for MDR and\nnalidixic acid resistant typhoid fever.Participants\nPatients were eligible to be included in the study if they had\nclinically suspected or culture confirmed uncomplicated typhoid\nfever and if fully informed written consent had been obtained. For\nchildren, consent was obtained from the parent. Exclusion criteria\nwere pregnancy, age under 6 months, history of hypersensitivity to\neither of the trial drugs, any signs of severe typhoid fever (shock,\ndeep jaundice, encephalopathy, convulsions, bleeding, suspicion or\nevidence of gut perforation), or previous reported treatment with a\nfluoroquinolone antibiotics, a third generation cephalosporine or\nmacrolide antibiotics within one week prior to hospital admission.\nThe study sites and ethical approval\nThe study was conducted at three hospitals in the south of\nVietnam.", "start_char_idx": 2636, "end_char_idx": 4256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f71fe3d0-a17e-420f-830a-5501ace567b3": {"__data__": {"id_": "f71fe3d0-a17e-420f-830a-5501ace567b3", "embedding": null, "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "d581863108ada8e2c73f5345f5664510f297c7b2e666adaaa40fd62cfedb5302", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "183b296c-ed4d-4070-8252-25568fbc2eae", "node_type": "1", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "4f735f9628eb9288fdaaeb5a06846eedbf2b5f43a6bce7341575b598cf4a3583", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87029fc9-73d8-4fd0-93a4-c84944fba0c9", "node_type": "1", "metadata": {}, "hash": "a748a4a170a2226fc3b1a6b146b7c3787638b8a51ed558ce12a0b19532149b26", "class_name": "RelatedNodeInfo"}}, "text": "The study sites and ethical approval\nThe study was conducted at three hospitals in the south of\nVietnam.\nAdult and paediatric patients were recruited at the Hospital for\nTropical Diseases in Ho Chi Minh City, at the Dong Thap\nProvincial hospital in Cao Lanh, Dong Thap province and at the\nAn Giang Provincial hospital in Long Xuyen, An Giang province.\nThe study was approved by the Ethical and Scientific\nCommittee of the Hospital for Tropical Diseases in Ho Chi Minh\nCity and the Oxford University Tropical Research Ethics\nCommittee (OXTREC), UK for all three study sites. The clinical\nand microbiological data from the first 40 patients recruited to\neach arm of the study were sent to the independent Data Safetyand Monitoring Committee for their advice regarding the\ncontinuation of the study. The study was not stopped.\nIntervention\nAccording to their randomisation number patients were\nassigned to oral treatment with either 20 mg/kg azithromycin\n(Zithromax Hsuspension, Pfizer, USA; 200 mg/5 mL or Zithro-\nmaxHtablets, Pfizer, USA; 500 mg/tablet) or 10 mg/kg gatiflox-\nacin (Tequin H, Bristol-Myers Squibb, USA; 400 mg/tablet) once\ndaily for 7 days. Tablets were cut to obtain the appropriate study\ndosage and administered with water. Inevitably, the dose\nadministered was an estimate of 10 mg/kg/day of gatifloxacin\nor 20 mg/kg/day of azithromycin (number of tablets or\nproportions of tablets were documented in the CRFs).", "start_char_idx": 4152, "end_char_idx": 5581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87029fc9-73d8-4fd0-93a4-c84944fba0c9": {"__data__": {"id_": "87029fc9-73d8-4fd0-93a4-c84944fba0c9", "embedding": null, "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "672a39ab-7a7b-4663-acfc-5275cf133ba1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "d581863108ada8e2c73f5345f5664510f297c7b2e666adaaa40fd62cfedb5302", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f71fe3d0-a17e-420f-830a-5501ace567b3", "node_type": "1", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "06056e519ef079224f233d3fe0b2134fb6fa7c96d46b5eb03b1e707b27ca29f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7a5ac4b-9026-4335-bf63-1f522999e1d6", "node_type": "1", "metadata": {}, "hash": "4dc2d124e06858cfb37c9ffe19ae1da737eae34b643b9be9b16cf6445ae481e1", "class_name": "RelatedNodeInfo"}}, "text": "Gatifloxacin\nwas only available as tablets, which were cut to obtain the\nappropriate dosage and crushed if necessary for children.\nThe maximum dose of azithromycin was 1 g per day. All drugs\nwere purchased commercially.\nProcedures\nIn-patient procedures. On admission to the hospital the\npatient\u2019s full history was taken, a standard clinical examinationwas performed and axillary temperature, weight and height were\nmeasured. Before treatment, full blood counts including white\nblood differential counts, serum aspartate transaminase (AST),\nserum alanine transaminase (ALT) and bilirubin were checked and\nblood cultures were obtained. For adult patients, creatinine, blood\nurea nitrogen (BUN) and glucose levels were additionally\nmeasured. In some patients bone marrow cultures were\nobtained. Urines were checked with dipstick and pre-treatment\nstool cultures were obtained. Chest X-ray and abdominal\nultrasound were performed and repeated as clinically indicated.\nRandomisation and initiation of therapy took place either\nimmediately on admission to hospital or patients were observed\nuntil results of blood tests including blood cultures were available\nand then randomised. Vital signs including measurement of\naxillary temperatures were measured and recorded every 6 hours\n(at 6, 12, 18 and 24 hours) until discharge. Patients were examinedTreatment of Typhoid Fever\nPLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 5582, "end_char_idx": 7017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7a5ac4b-9026-4335-bf63-1f522999e1d6": {"__data__": {"id_": "d7a5ac4b-9026-4335-bf63-1f522999e1d6", "embedding": null, "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d85b90-bd53-462a-a8e3-d8178e418217", "node_type": "4", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "bd6927eb504ba0d1974ddf9067a5976bd815f812964a36e7da1ea427bbaf97b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87029fc9-73d8-4fd0-93a4-c84944fba0c9", "node_type": "1", "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "575dcb39c133adaa5614cf6f2d719d0f03d9d96db65f94311fc50917802aafaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c506829-03c3-4e6f-b38a-0d1e52127ff2", "node_type": "1", "metadata": {}, "hash": "226037e3a19f5ef97e319e3bb15c7af875bb600a60a8891bfa4bc91097f3c356", "class_name": "RelatedNodeInfo"}}, "text": "daily until discharge from hospital, with particular reference to\nclinical symptoms, FCT, side effects of the drug and any\ncomplication of the disease. Additionally laboratory tests werescheduled if clinically indicated. All adverse events were recorded.On day 7 to 9 after the start of treatment full blood counts, liverfunction tests, blood and stool cultures were checked. In case of\ninsufficient response to therapy, development of complications or\ndrug-associated adverse events, the initial treatment wassuspended and parenteral ceftriaxone (2 g per day) in twodivided doses was used as rescue treatment for 10 days.\nFollow-up procedures. Out-patient follow-up appointments\nwere scheduled at 1 month, 3 months and 6 months after\ndischarge from hospital to seek evidence for relapse (1 month visit)\nand check for chronic typhoid carriage (all visits). At theseappointments a full history was taken, relevant examinationsperformed and stool cultures obtained. Blood or bone marrowcultures were only obtained if clinical symptoms were indicative of\nacute infection. If patients did not attend their follow up\nappointment, they were reminded by letter or a member of thestudy team visited their home. If stool samples were not available,a rectal swab was obtained.\nPatients with convalescent stool carriage of S. typhi orS. paratyphi\nA were retreated according to the sensitivity of the isolate and werefurther followed up. Ultrasound was performed to exclude biliary\nor kidney stones if carriage was persistent.", "start_char_idx": 0, "end_char_idx": 1514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c506829-03c3-4e6f-b38a-0d1e52127ff2": {"__data__": {"id_": "0c506829-03c3-4e6f-b38a-0d1e52127ff2", "embedding": null, "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d85b90-bd53-462a-a8e3-d8178e418217", "node_type": "4", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "bd6927eb504ba0d1974ddf9067a5976bd815f812964a36e7da1ea427bbaf97b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7a5ac4b-9026-4335-bf63-1f522999e1d6", "node_type": "1", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "484c137b814f5efce041adfebd56b5892ed889e1243129d6d94eb9d9787a5dbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8716d68a-85f5-4cea-a2bf-c866d40291fb", "node_type": "1", "metadata": {}, "hash": "3108d742085c6076d86aa3d0e216815da63ae945c1e4f3e2dd892d9370fc52cd", "class_name": "RelatedNodeInfo"}}, "text": "paratyphi\nA were retreated according to the sensitivity of the isolate and werefurther followed up. Ultrasound was performed to exclude biliary\nor kidney stones if carriage was persistent.\nMicrobiology\nFive to 8 mL of blood was collected from adults and inoculated\ninto Bactec Plus Aerobic Blood bottles, and 3 to 5 mL of bloodfrom children was inoculated into Bactec Peds Plus culture bottles(Becton Dickinson, New Jersey, USA). The bottles were incubated\nat 37 uC in the BACTEC 9050 automated analyser for 7 days and\nsub-cultured according to standard methods when the machineindicated a positive signal, or incubated at 37 uC in a standard\nlaboratory incubator (An Giang hospital) and examined daily.\nStool samples or rectal swabs were inoculated onto MacConkey\nagar and Xylose Lysine Decarboxylase (XLD) agar plates, and in10 mL of selenite F broth. Plates and broth were incubated at37uC overnight and the broth was sub-cultured on MacConkey\nand XLD agar plates the next morning.\nIsolates were screened using standard biochemical tests and S.\ntyphi and S. paratyphi A were identified using API20E (bioMerieux,\nParis, France) and slide agglutination with specific antisera\n(Murex, Dartford, UK).\nAntimicrobial susceptibility testing was performed by disc\ndiffusion according to Clinical Laboratory Standards Institute\n(CLSI) guidelines [12], using CLSI breakpoints [13].", "start_char_idx": 1326, "end_char_idx": 2700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8716d68a-85f5-4cea-a2bf-c866d40291fb": {"__data__": {"id_": "8716d68a-85f5-4cea-a2bf-c866d40291fb", "embedding": null, "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d85b90-bd53-462a-a8e3-d8178e418217", "node_type": "4", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "bd6927eb504ba0d1974ddf9067a5976bd815f812964a36e7da1ea427bbaf97b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c506829-03c3-4e6f-b38a-0d1e52127ff2", "node_type": "1", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "e8ff6fcc69f53dcb4f64e4f8bd5d8a55575b32353b7ebc39628352a6fd0909d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f96b4c1c-1a97-4e92-b582-082ea78bdaba", "node_type": "1", "metadata": {}, "hash": "f2108f23f83d2eef55ca6b1a7b88a89acd65fc286337f8fa2057b6a3dab45968", "class_name": "RelatedNodeInfo"}}, "text": "Antimicrobial susceptibility testing was performed by disc\ndiffusion according to Clinical Laboratory Standards Institute\n(CLSI) guidelines [12], using CLSI breakpoints [13]. Antimicro-\nbial agents tested were: ampicillin, chloramphenicol, trimetho-prim-sulfamethoxazol, nalidixic acid, ofloxacin, ciprofloxacin andceftriaxone (Oxoid, Basingstoke, UK). Minimum Inhibitory\nConcentrations (MICs) for amoxicillin, chloramphenicol, nalidixic\nacid, ofloxacin, ciprofloxacin, gatifloxacin, ceftriaxon and azith-romycin were determined by E-test (AB Biodisk, Solna, Sweden).Multidrug resistance (MDR) of isolates was defined as resistance tochloramphenicol (MIC $32mg/mL), ampicillin (MIC $32mg/\nmL) and trimethoprim-sulfamethoxazole (MIC $8/152 mg/mL).\nNalidixic acid resistance was defined as an MIC $32mg/mL. The\nCLSI breakpoints for ofloxacin and gatifloxacin were #2mg/mL\nsusceptible and $8mg/mL resistant, for ciprofloxacin #1mg/mL\nsusceptible and $4mg/mL resistant and for ceftriaxone #8mg/\nmL susceptible and $64mg/mL resistant. There were no CLSI\nMIC breakpoints for azithromycin [13].", "start_char_idx": 2526, "end_char_idx": 3613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f96b4c1c-1a97-4e92-b582-082ea78bdaba": {"__data__": {"id_": "f96b4c1c-1a97-4e92-b582-082ea78bdaba", "embedding": null, "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d85b90-bd53-462a-a8e3-d8178e418217", "node_type": "4", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "bd6927eb504ba0d1974ddf9067a5976bd815f812964a36e7da1ea427bbaf97b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8716d68a-85f5-4cea-a2bf-c866d40291fb", "node_type": "1", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "c7bf4728401b7fbe0185ccdba6df1962b6940a608b6645f416563e102308ddbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e753db88-bc85-46f5-9f8d-1029109515e5", "node_type": "1", "metadata": {}, "hash": "e77ab21969940d25ba2cd99a168c80f055feb842470ad48b6468a30ab869149d", "class_name": "RelatedNodeInfo"}}, "text": "There were no CLSI\nMIC breakpoints for azithromycin [13]. The control strains usedfor all susceptibility tests were E. coli ATCC 25922, Pseudomonas\naeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213.All cultures, identification of S. typhi and S. paratyphi A and disc\ndiffusion were performed at the three study sites. All isolates were\nsent to the Hospital for Tropical Diseases, Ho Chi Minh City, for\nconfirmation of identity, susceptibility testing and MIC testing.\nOutcomes of the study\nThe primary endpoint of the study was the resolution of fever\n(fever clearance time, FCT), which was defined as the time from\nthe start of the antibiotic treatment to when the axillary\ntemperature first fell #37.5 uC and remained there for at least\n48 hours. Secondary endpoints were the overall failure to\ntreatment, which was defined a priori as any of the following:\nclinical failure (persistence of fever and symptoms two days after\nthe end of treatment, i.e. on day 10) or need for re-treatment due\nto insufficient treatment response as judged by the treating\nphysician; microbiological failure (positive blood culture on day 7\nto 9 after the start of treatment); the development of typhoid fever-\nrelated complications during hospital-stay; the occurrence of\nrelapse (symptoms and signs suggestive of typhoid fever) within 1\nmonth after completion of treatment or the detection of faecal\ncarriage of S. typhi at the follow-up visits at 1, 3 and 6 months (to\nexclude faecal carriage a minimum of two consecutive follow-up\nvisits had to be attended).", "start_char_idx": 3556, "end_char_idx": 5106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e753db88-bc85-46f5-9f8d-1029109515e5": {"__data__": {"id_": "e753db88-bc85-46f5-9f8d-1029109515e5", "embedding": null, "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d85b90-bd53-462a-a8e3-d8178e418217", "node_type": "4", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "bd6927eb504ba0d1974ddf9067a5976bd815f812964a36e7da1ea427bbaf97b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f96b4c1c-1a97-4e92-b582-082ea78bdaba", "node_type": "1", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "ab983b85e0078eecb6bd72a6ec59a0ecb803127f0db40042a2a0245f6f412af9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e508ff4-a59a-4527-b3f0-c57ab152f418", "node_type": "1", "metadata": {}, "hash": "327a1556a691bcb7496e952aaacfd3114592da461d4d4a8bd4256fd8140969b8", "class_name": "RelatedNodeInfo"}}, "text": "Sample Size\nThe primary outcome measure for the study was the fever\nclearance time (FCT).\nPrevious studies that used azithromycin to treat typhoid fever\npatients, reported a mean fever clearance time of 130 hours [7]\nand 139 hours [8]. For gatifloxacin, clinical observations from a\nsmall number of typhoid fever patients were available andindicated a mean FCT of 76 hours. We calculated that 139\npatients with culture-confirmed typhoid fever would be needed in\neach treatment arm to detect a Hazard Ratio of 1.40 with two-\nsided alpha of 0.05 and power of 0.80 [14]. Therefore, assuming a\nmedian fever clearance time of 130 hours for azithromycin, the\nsample size of 140 patients with culture-confirmed typhoid fever in\neach arm would give power of at least 0.80 to detect a difference\nbetween treatments if the fever clearance time in the gatifloxacin\ngroup was 92 hours or less.\nRandomization procedures and assignment of\nintervention (sequence generation, allocationconcealment, implementation)\nAn administrator independent from the study generated the\nrandom number sequence in Excel using RAND function. These\nrandomised codes were blocked in a size of 50. Treatment\nassignments were folded and kept in opaque, sealed, sequentially\nnumbered envelopes at all three study sites. Due to logistic reasons\nrandomisation was not stratified by centre.\nAfter all inclusion and exclusion criteria were checked, and\ninformed consent given, the study doctor opened the envelope todetermine which treatment the subject would receive. The sealed\nenvelopes were opened in strict numeric sequence.\nBlinding\nThis study was conducted as an open study.", "start_char_idx": 5107, "end_char_idx": 6747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e508ff4-a59a-4527-b3f0-c57ab152f418": {"__data__": {"id_": "9e508ff4-a59a-4527-b3f0-c57ab152f418", "embedding": null, "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d85b90-bd53-462a-a8e3-d8178e418217", "node_type": "4", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "bd6927eb504ba0d1974ddf9067a5976bd815f812964a36e7da1ea427bbaf97b0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e753db88-bc85-46f5-9f8d-1029109515e5", "node_type": "1", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "dcce44f2801e1a8af2eb952fae99b6dbcd5fda17b470a7fe83b8e10033471d45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a38d1522-b9c0-4b43-87ec-a72cc00f6784", "node_type": "1", "metadata": {}, "hash": "49d60d856a18b92c3efa6f3f0d60aea51930f7dc19db32f7885bccf4a2fa89a0", "class_name": "RelatedNodeInfo"}}, "text": "The sealed\nenvelopes were opened in strict numeric sequence.\nBlinding\nThis study was conducted as an open study.\nStatistical methods\nBinary outcomes (clinical failure, microbiological failure,\ntyphoid fever-related complications) were compared between the\ntwo treatment groups using Fisher\u2019s exact test, assuming the worstcase scenario (all lost to follow up treated as failures). The un-Treatment of Typhoid Fever\nPLoS ONE | www.plosone.org 3 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 6635, "end_char_idx": 7116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a38d1522-b9c0-4b43-87ec-a72cc00f6784": {"__data__": {"id_": "a38d1522-b9c0-4b43-87ec-a72cc00f6784", "embedding": null, "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "879863abbb34c1c87ba474b0c98917263ff26aba381fae93194e430e7d6810ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e508ff4-a59a-4527-b3f0-c57ab152f418", "node_type": "1", "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "07a7c0e69ce2cf92b23500d57f4f1c79019f77903dd586a10ea924a035020b00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d92ca9cf-dfef-45e0-940e-ca3bd23ad6d9", "node_type": "1", "metadata": {}, "hash": "2da5ddc129474b52be0efc77624b0b02abe7e714415cd6211941d900884f553f", "class_name": "RelatedNodeInfo"}}, "text": "adjusted Odds Ratio (OR) and Cornfield\u2019s 95% confidence\ninterval [15] were calculated to show the relative risk of developing\nindividual secondary outcomes (clinical, microbiological failure,\ntyphoid fever-related complications) in the gatifloxacin group\ncompared to the azithromycin group.\nFever clearance time, time to relapse and time to overall failure\nwere analysed using survival methods. The time to overall failure\nequaled the earliest time individual failure was recorded. Kaplan-\nMeier estimates of probabilities of each event were calculated at\nany time-point, and they were compared between the two\ntreatment groups using the log-rank test. Data of patients who\nwere lost to follow-up were censored at the time of the last\nrecorded outcome. The Hazard Ratio was derived from Cox\nproportional hazard model [16].\nAll patients with positive blood or bone marrow culture for S.\ntyphi and S. paratyphi A (per protocol analysis) and separately all\nrandomised patients (intention to treat analysis) were analysed.\nAll data were recorded prospectively into individual Case\nRecord Forms (CRF) and entered into an electronic database (Epi\nInfo 2003, CDC, Atlanta, USA) and double-checked.\nAnalysis was performed using STATA version 8.0 (Stata\nCorporation, Texas, USA) statistical software program.\nResults\nParticipant flow and recruitment\nDuring the study period, 460 patients were assessed for\neligibility (Figure 1). One hundred and two patients were non-\neligible, the main reason was the reported previous use of\nfluoroquinolone, macrolid or third generation cephalosporin\nantibiotics (41 patients) in the week before hospitalisation.", "start_char_idx": 0, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d92ca9cf-dfef-45e0-940e-ca3bd23ad6d9": {"__data__": {"id_": "d92ca9cf-dfef-45e0-940e-ca3bd23ad6d9", "embedding": null, "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "879863abbb34c1c87ba474b0c98917263ff26aba381fae93194e430e7d6810ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a38d1522-b9c0-4b43-87ec-a72cc00f6784", "node_type": "1", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "73f58bb02a6f5c9d4c9aa6c1da21ee2738f67a2826ab75a7c236a5404adbe297", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c677c62b-7286-4c54-bb71-fcdbdb60e215", "node_type": "1", "metadata": {}, "hash": "32533e4e4c97ca1c5c179431152425717e1ceb7ed6db3fbb5c319a96edf0205b", "class_name": "RelatedNodeInfo"}}, "text": "Between April 2004 and August 2005, 358 patients with\nsuspected typhoid fever were randomised to receive either\ngatifloxacin or azithromycin. Two hundred eighty-eight of these\npatients had blood or bone marrow confirmed typhoid fever and\n70 patients were culture negative for S. typhi . One culture positive\npatients was excluded from the per protocol analysis (PP), because\nhe had received ciprofloxacin before entry to the trial. The PP\ngroup consisted of 287 patients, 145 in the gatifloxacin group and\n142 in the azithromycin group. All PP patients, except two in the\nazithromycin group, finished the full course of treatment.\nThe total number patients visiting the follow-up at 1 month was\n275 out of 287 (96%), at 3 months 268 out of 287 (93%), at 6\nmonths 128 out of 287 (44%) patients.\nNumbers analysed\nAll 358 randomised patients were analysed in the intention to\ntreat (ITT) analysis. Two hundred and eighty-seven patients with\nculture confirmed typhoid fever, 145 treated with gatifloxacin and\n142 with azithromycin, were analysed in the pre-specified PP\nanalysis.\nBaseline Data\nThe median age of patients recruited in this trial was 11 years\n(range 1\u201341) in the PP group.\nThe baseline characteristics of the patients were similar in the\ntwo treatment groups and in the culture negative patients (Table 1).\nPatients with suspected and blood culture confirmed typhoid\nfever were eligible for this trial.", "start_char_idx": 1641, "end_char_idx": 3054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c677c62b-7286-4c54-bb71-fcdbdb60e215": {"__data__": {"id_": "c677c62b-7286-4c54-bb71-fcdbdb60e215", "embedding": null, "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "879863abbb34c1c87ba474b0c98917263ff26aba381fae93194e430e7d6810ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d92ca9cf-dfef-45e0-940e-ca3bd23ad6d9", "node_type": "1", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "9c2238d9f5f3596bbcc7de383afd166e67b5d09fed247f6a1ed10728d1cc6088", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "937ff68d-1aa4-46a3-a630-9a2eefdf0784", "node_type": "1", "metadata": {}, "hash": "b7eb883f5905b09ced4d72b2091b8ee0eae2435955772067f3a1116522993597", "class_name": "RelatedNodeInfo"}}, "text": "The baseline characteristics of the patients were similar in the\ntwo treatment groups and in the culture negative patients (Table 1).\nPatients with suspected and blood culture confirmed typhoid\nfever were eligible for this trial. In the PP group, the median delay\nin time between hospital admission and randomisation was 3 days\n(interquartile range 1\u20134) in the gatifloxacin group and 3 days\n(interquartile range 2\u20134) in the azithromycin group. In the ITT\ngroup, the median delay in time between hospital admission andrandomisation was 2 days (interquartile range 0\u20134) in thegatifloxacin group and 3 days (interquartile range 1\u20134) in the\nazithromycin group.\nProtocol deviations and modifications\nAt one study site, the An Giang Provincial Hospital, the follow-\nup visit at 6 months was not possible for logistic reasons. It was\ntherefore agreed to carry out two follow-up visits at 1 and 3\nmonths and to schedule additional (cross-sectional) follow-up dates\nto invite as many patients as possible to a third follow-up visit.\nFrom the PP population, 22 out of 91 patients in the gatifloxacin\narm and 17 out of 87 patients in the azithromycin arm attended\nthe third visit.\nOutcomes and estimation\nPrimary outcomes. There was no significant difference in\nthe resolution of fever (FCT) between the two treatment groups\n(Table 2).", "start_char_idx": 2825, "end_char_idx": 4149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "937ff68d-1aa4-46a3-a630-9a2eefdf0784": {"__data__": {"id_": "937ff68d-1aa4-46a3-a630-9a2eefdf0784", "embedding": null, "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "879863abbb34c1c87ba474b0c98917263ff26aba381fae93194e430e7d6810ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c677c62b-7286-4c54-bb71-fcdbdb60e215", "node_type": "1", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "f50f6944ce6af678369012dd54635a7e6fe9decd67ca5de5d6001bbc198d3349", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfb884ef-e5c0-48e9-b011-4b40eacd5d32", "node_type": "1", "metadata": {}, "hash": "7552e70c2df5ea12aa9ba2da11d1b7d4a08ca21a7df7c5d46b7b48aa3ff17802", "class_name": "RelatedNodeInfo"}}, "text": "Outcomes and estimation\nPrimary outcomes. There was no significant difference in\nthe resolution of fever (FCT) between the two treatment groups\n(Table 2).\nBy PP analysis, the median FCT was 106 hours in both\ntreatment arms (95% Confidence Interval [CI]; 94\u2013118 hours for\ngatifloxacin versus 88\u2013112 hours for azithromycin), (logrank test\np= 0.984, HR [95% CI] = 1.0 [0.80\u20131.26]). The Kaplan-Meier\nsurvival curve for the fever clearance time is shown in Figure 2. At\nday 7, fever clearance rate was 82.8% (95% CI; 76.2%\u201388.4%) in\nthe gatifloxacin group and 80.5% (95% CI; 73.6 %\u201386.6 %) in the\nazithromycin group.\nIn the ITT population, the median FCT was 100 hours in both\ntreatment arms (95% CI; 92\u2013106 hours for gatifloxacin versus 88\u2013\n112 hours for azithromycin), (logrank test p= 0.914, HR [95%\nCI] = 1.01 [0.82\u20131.25]). At day 7, fever clearance rate was 84.2%\n(95% CI; 78.5%\u201389%) in the gatifloxacin group and 82.6% (95%\nCI; 76.5%\u201387.9%) in the azithromycin group (Figure 3).\nSecondary outcomes. There was no death in the study.", "start_char_idx": 3995, "end_char_idx": 5027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfb884ef-e5c0-48e9-b011-4b40eacd5d32": {"__data__": {"id_": "cfb884ef-e5c0-48e9-b011-4b40eacd5d32", "embedding": null, "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "879863abbb34c1c87ba474b0c98917263ff26aba381fae93194e430e7d6810ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "937ff68d-1aa4-46a3-a630-9a2eefdf0784", "node_type": "1", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "989e68e099c98b7ec56c900f9080a08bd0eca492fb8ca82e21cc29ede712fcfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6216f214-1228-4ee3-8cbe-12685d7d54f0", "node_type": "1", "metadata": {}, "hash": "0f06d9e0aa24818e8b0ffe77ddc7eef018f01552e3c50bea1f0c12c9717a6608", "class_name": "RelatedNodeInfo"}}, "text": "Secondary outcomes. There was no death in the study.\nThere was no significant difference in overall failure to\ntreatment between the two groups (Table 2).\nBy PP analysis, the number of patients that showed overall\nfailure to treatment was 13/145 (9%) in the gatifloxacin group and\n13/140 (9.3%) in the azithromycin group (logrank test p= 0.854,\nHR [95% CI] = 0.93 [0.43\u20132.0]), or when assuming the worst case\nscenario, that all dropped-out patients were failures, 15/142\n(10.6%) failures in the azithromycin group (logrank test p= 0.570,\nHR [95% CI] = 0.81 [0.38\u20131.7]). Figure 4 shows the proportion of\npatients failing through time after the start of treatment.\nIn the azithromycin arm, more than one failure event occurred\nin individual patients (Table 2). Clinical failure occurred in 6/145\n(4.3%) patients in the gatifloxacin group and in 6/140 (4.2%) in\nthe azithromycin group ( p= 1.000, OR [95% CI] = 0.96 [0.25\u2013\n3.7]). Three patients in each study arm were re-treated with\nceftriaxone, the other patients resolved their symptoms within24 hours.", "start_char_idx": 4975, "end_char_idx": 6027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6216f214-1228-4ee3-8cbe-12685d7d54f0": {"__data__": {"id_": "6216f214-1228-4ee3-8cbe-12685d7d54f0", "embedding": null, "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bf3c95e5-c8a7-4512-a7f6-f49242c241b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "879863abbb34c1c87ba474b0c98917263ff26aba381fae93194e430e7d6810ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfb884ef-e5c0-48e9-b011-4b40eacd5d32", "node_type": "1", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "b2083e090f1e0ff10de726f4703eb8dcf2ca3f2c81fd1ae5d45838d3ac7d4462", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "927c24b9-a4be-4434-9fcd-ce85f082d353", "node_type": "1", "metadata": {}, "hash": "ee21e49b14e56052c98ed6fd0b55ae044111c8288347807d7a4a602c567c6685", "class_name": "RelatedNodeInfo"}}, "text": "Three patients in each study arm were re-treated with\nceftriaxone, the other patients resolved their symptoms within24 hours.\nMicrobiological failure was seen in 2 out of 145 patients in the\ngatifloxacin arm (1.4%) and in 3 out of 140 (2.2%) in the\nazithromycin arm ( p= 0.680, OR [95% CI] = 0.64 [0.05\u20135.7]).\nTwo of the azithromycin recipients showed additionally signs of\nclinical failure.\nThere were no typhoid fever-related complications in the 145\ngatifloxacin patients compared to 8 out of 140 (5.7%) patients in\nthe azithromycin arm ( p= 0.003, OR [95% CI] = 0 [0\u20130.4]). Two\nazithromycin recipients developed signs of liver dysfunction\n(elevated AST and ALT, deepening of jaundice) in addition to\nsigns of clinical failure. Study treatment was continued and\nsymptoms resolved by the time of discharge. Four patients, threechildren and one adult, suffered from gastrointestinal bleeding on\nday 3, day 5 (2 cases) and day 7 of treatment respectively, three\npatients received blood transfusions. One of these patientsTreatment of Typhoid Fever\nPLoS ONE | www.plosone.org 4 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 5902, "end_char_idx": 7016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "927c24b9-a4be-4434-9fcd-ce85f082d353": {"__data__": {"id_": "927c24b9-a4be-4434-9fcd-ce85f082d353", "embedding": null, "metadata": {"page_label": "5", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0db985ec-628a-488b-8fb9-661208994002", "node_type": "4", "metadata": {"page_label": "5", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "c863dcd7369790d8660ecdd978f963ba539224f6c7aa452e706c81787e834d70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6216f214-1228-4ee3-8cbe-12685d7d54f0", "node_type": "1", "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "769f918e6fa6c096ee6261f0dff532eb7f42183840a6c655fce01134ee1725d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05925efc-e111-4144-ba67-997207668dff", "node_type": "1", "metadata": {}, "hash": "fd2704d1f4e19c23f971bee8ba7795efb7bc6cf62acf566d1e4af8bd7d7fb64c", "class_name": "RelatedNodeInfo"}}, "text": "developed shock but responded to intravenous fluids and\nsupportive treatment. Treatment was discontinued immediatelyin all the patients and re-treatment with ceftriaxone was initiated.Two adult patients developed pneumonia during treatment.\nRelapse was evaluated only in patients that were initially\ncategorised as successfully treated, patients with clinical failure,microbiological failure or complications were not evaluated. Fourpatients out of 137 (2.9%) relapsed in the gatifloxacin groupcompared to 0/127 in the azithromycin group (logrank test\np= 0.052, HR [95% CI] = not estimable due to zero observationsin one group), (Figure 5). These relapses with symptoms suggestive\nof typhoid fever occurred on day 7, 11, 13 and 15 respectively,after completion of treatment, three patients were confirmedculture positive for S. typhi . One patient developed acute\nrespiratory distress syndrome (ARDS) and needed ventilation.The patient was treated with ceftriaxone and perfloxacine andsubsequently made a complete recovery.\nChronic faecal carriage was evaluated in patients who attended\nat least two follow-up appointments, 137 in the gatifloxacin group\nand 131 in the azithromycin group. Only one patient with chronic\nFigure 1. Profile of the Trial.\ndoi:10.1371/journal.pone.0002188.g001Treatment of Typhoid Fever\nPLoS ONE | www.plosone.org 5 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 0, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05925efc-e111-4144-ba67-997207668dff": {"__data__": {"id_": "05925efc-e111-4144-ba67-997207668dff", "embedding": null, "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "609f90f6-301f-406c-981c-d012a6b828f2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "b280bf91df9c7263656eae9821e212b957d4730c4bec6b0c27b4ae37a48d5442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "927c24b9-a4be-4434-9fcd-ce85f082d353", "node_type": "1", "metadata": {"page_label": "5", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "c863dcd7369790d8660ecdd978f963ba539224f6c7aa452e706c81787e834d70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb226240-ce85-4610-9086-342a37977f38", "node_type": "1", "metadata": {}, "hash": "fb95bf34e62daad342bfb0a43d67b9a406f435c93a081150c4829d0de680c8ef", "class_name": "RelatedNodeInfo"}}, "text": "Table 1. Baseline characteristics of culture confirmed patients (PP analysis) and culture negative patients.\nCharacteristicsCulture confirmed patients treated withBlood culture negative\npatients, n = 70\nGatifloxacin, n = 145 Azithromycin, n = 142\nMedian age in years (range) 11 (2\u201330) 11 (1\u201341) 9 (2\u201342)\nNumber of children defined as age under 15 (%) 109 (75.2) 101 (71.1) 56 (80)\nNumber of males (%) 71 (49) 76 (53.5) 29 (41)Median weight in kilograms (range) 25 (8.5\u201355) 24.5 (9.5\u201357) 19.5 (10.5\u201353)\nMedian duration of fever before admission in days (range) 7 (2\u201330) 7 (2\u201330) 7 (3\u201330)\nNumber of patients who received pretreatment (%)* 21 (14.5) 18 (12.7) 16 (22.9)Median temperature at admission in uC (range) 39 (37\u201340.5) 39 (37.3\u201341) 38.75 (37\u201340)\nHepatomegaly, number of patients (%) 69 (47.6) 63 (44.4) 36 (51.4)\nSplenomegaly, number of patients (%) 17 (11.7) 14 (9.8) 2 (2.9)Abdominal pain, number of patients (%) 82 (56.5) 76 (53.5) 43 (61.4)\nWeight loss, number of patients (%) 69 (47.", "start_char_idx": 0, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb226240-ce85-4610-9086-342a37977f38": {"__data__": {"id_": "cb226240-ce85-4610-9086-342a37977f38", "embedding": null, "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "609f90f6-301f-406c-981c-d012a6b828f2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "b280bf91df9c7263656eae9821e212b957d4730c4bec6b0c27b4ae37a48d5442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05925efc-e111-4144-ba67-997207668dff", "node_type": "1", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "7c851aad6f4450f8f0eae10f7093bb8f801a9da924ac16fadde1d15e5519ce7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7faa8a9f-e98b-4db7-bfe5-e8ac416c6810", "node_type": "1", "metadata": {}, "hash": "67855acf328b19eed294c952dad6c492d4fc809aa6f3787e9e1d15ddda0a31a3", "class_name": "RelatedNodeInfo"}}, "text": "9)Abdominal pain, number of patients (%) 82 (56.5) 76 (53.5) 43 (61.4)\nWeight loss, number of patients (%) 69 (47.6) 71 (50) 21 (30)\nVomiting, number of patients (%) 47 (32.4) 54 (38) 19 (27.1)Diarrhoea, number of patients (%) 95 (65.5) 82 (57.7) 49 (70)\nMild jaundice, number of patients (%) 12 (8.3) 20 (14.1) 1 (1.4)\nMedian haematocrit in % (range) 34.3 (19.2\u201354.3) 34.6 (20.7\u201360.5) 34.2 (24.6\u201346.7)Median white cell count, 10\n9/L (range) 6.9 (2\u201317.2) 7.05 (2.4\u201316.8) 7.25 (2.8\u201311.7)\nMedian platelet count, 109/L (95% CI, range) 172 (34\u2013500) 172.5 (45\u2013578) 208 (51\u2013496)\nMedian AST, U/L(range) 85 (16.9\u2013773) 72 (17.6\u20131190) 50.1 (11\u2013533)Median ALT, U/L (range) 67.4 (10.3\u2013276) 59.4 (10.2\u2013734) 44.1 (10\u2013375)\nNumbers of S.typhi /S.", "start_char_idx": 880, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7faa8a9f-e98b-4db7-bfe5-e8ac416c6810": {"__data__": {"id_": "7faa8a9f-e98b-4db7-bfe5-e8ac416c6810", "embedding": null, "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "609f90f6-301f-406c-981c-d012a6b828f2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "b280bf91df9c7263656eae9821e212b957d4730c4bec6b0c27b4ae37a48d5442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb226240-ce85-4610-9086-342a37977f38", "node_type": "1", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "fb562f445ad09739f34644f642a5713069768149e7c71a734e26d3a8b79bb364", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0aaac66-3403-4944-b48c-6a36ed80f016", "node_type": "1", "metadata": {}, "hash": "46c024ff2394b3eef57c6db013f3aed1538b76486e9e9c1ee7ddd068dc7423ce", "class_name": "RelatedNodeInfo"}}, "text": "U/L (range) 67.4 (10.3\u2013276) 59.4 (10.2\u2013734) 44.1 (10\u2013375)\nNumbers of S.typhi /S.paratyphi A isolated from blood cultures 144/1 138/4 0\nPositive pretreatment faecal cultures, numbers (%) 11/124 (8.9) 6/118 (5.1) 0\nAST, Serum Aspartate Aminotransferase AST (normal range, 12\u201330 U/L).\nALT, Serum Alanine Aminotransferase ALT (normal range, 13\u201340 U/L).*Treatment with amoxicilline or cotrimoxazole prior to hospital admission.\ndoi:10.1371/journal.pone.0002188.t001\nTable 2.", "start_char_idx": 1530, "end_char_idx": 1999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0aaac66-3403-4944-b48c-6a36ed80f016": {"__data__": {"id_": "e0aaac66-3403-4944-b48c-6a36ed80f016", "embedding": null, "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "609f90f6-301f-406c-981c-d012a6b828f2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "b280bf91df9c7263656eae9821e212b957d4730c4bec6b0c27b4ae37a48d5442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7faa8a9f-e98b-4db7-bfe5-e8ac416c6810", "node_type": "1", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "d95c6135f02acb04584d3f92a6bf42f84a3271a76f7e2cf68e3126732ea874c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed7f2783-2b31-48ad-9c5c-33816b54fd1c", "node_type": "1", "metadata": {}, "hash": "7b329fa4791fd4fe3aa9caee78c868fbac2398e267270ceb9e5eee3f1abff70c", "class_name": "RelatedNodeInfo"}}, "text": "*Treatment with amoxicilline or cotrimoxazole prior to hospital admission.\ndoi:10.1371/journal.pone.0002188.t001\nTable 2.\nOutcome Type Outcomes Sub-CategoriesTreatment group (n = 287)\nGatifloxacin n = 145 Azithromycin n = 142 p-Value\nPrimary Fever Clearance Time in hours (95% CI) 106 (94\u2013118) 106 (88\u2013112) 0.984 \u02c6\nSecondary Overall treatment failure, numbers of patients (%) 13/145 (9) 13/140 (9.3)\"0.854 \u02c6\nDid not complete full treatment course, n (%) 0 2\n*Clinical failure, n (%) 6/145 (4.3) 6/140 (4.2) 1.000#\n*Microbiological failure, n (%) 2/145 (1.4) 3/140 (2.2) 0.680#\n*Typhoid-fever related complications, n (%) 0/145 (0) 8/140 (5.7) 0.003#\nGastrointestinal bleeding 0 4\nPneumonia 0 2Liver dysfunction 0 2\nRelapse after discharge from hospital, n (%) 4/137 (2.9) 0/127 (0) 0.052 \u02c6\n1Number of patients with faecal carriage at follow-up, n (%) 1/137 (0.7) 0/131 (0)\n*Patients can fail in more than one subcategory.\n\"In the worst case scenario: 15/142 (10.6%) showed overall treatment failure in the azithromycin group, log rank test p = 0.570.", "start_char_idx": 1878, "end_char_idx": 2928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed7f2783-2b31-48ad-9c5c-33816b54fd1c": {"__data__": {"id_": "ed7f2783-2b31-48ad-9c5c-33816b54fd1c", "embedding": null, "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "609f90f6-301f-406c-981c-d012a6b828f2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "b280bf91df9c7263656eae9821e212b957d4730c4bec6b0c27b4ae37a48d5442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0aaac66-3403-4944-b48c-6a36ed80f016", "node_type": "1", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "53fa052d583ac1b21c6130fdeffcbba3f5fa4e2b44aa8f01d7cfedcbee5bf051", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4baef134-5231-4b7d-b791-c9a9196988c9", "node_type": "1", "metadata": {}, "hash": "fcfb80e8a10f7cc69ac7a5a7a85e21bc3663706bd84e2eefd2251a71825e184d", "class_name": "RelatedNodeInfo"}}, "text": "\"In the worst case scenario: 15/142 (10.6%) showed overall treatment failure in the azithromycin group, log rank test p = 0.570.\n\u02c6The pvalue is based on the log rank test.\n#The pvalue is based on Fisher\u2019s exact test.\n1Evaluated in patients who attended at least two follow-up visits.\ndoi:10.1371/journal.pone.0002188.t002Treatment of Typhoid Fever\nPLoS ONE | www.plosone.org 6 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 2800, "end_char_idx": 3214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4baef134-5231-4b7d-b791-c9a9196988c9": {"__data__": {"id_": "4baef134-5231-4b7d-b791-c9a9196988c9", "embedding": null, "metadata": {"page_label": "7", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7beec391-5b20-4fb3-9abc-41419b5d295f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "719c55fc235e5488495b3dc958f4d4967a3f00aceaa3d35172d76b62eb674516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed7f2783-2b31-48ad-9c5c-33816b54fd1c", "node_type": "1", "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "6eb9981fac3d55790cef36bcb5e4927dc62e903fca7b11beafdb44c522081ea8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "376f39d4-26b9-4d04-b712-4aefcef2eb04", "node_type": "1", "metadata": {}, "hash": "295f0f181fc845e991acd79d3bb48a59829d7a320a5370c9a572a21bccbd0084", "class_name": "RelatedNodeInfo"}}, "text": "faecal carriage was detected after 6 months (An Giang study site),\nthe patient had received gatifloxacin.\nIn the ITT analysis (all 358 randomised patients), overall\ntreatment failure was reported in 13 out of 185 (7%) in the\ngatifloxacin group compared to 14 out of 168 (8.4%) in theazithromycin group (logrank test p= 0.615, HR [95% CI] = 0.82\n[0.39\u20131.76]). One culture negative patient in the azithromycingroup had a positive blood culture on day 7 after start oftreatment. There were no clinical failures or typhoid fever-relatedcomplications in the culture negative patients.\nFigure 2. Proportion of culture confirmed patients still febrile. Kaplan-Meier survival curve showing the proportion of culture confirmed\npatients (PP analysis) still febrile through time by treatment group.doi:10.1371/journal.pone.0002188.g002\nFigure 3. Proportion of all randomised patients still febrile. Kaplan-Meier survival curve showing the proportion of all randomised patients\n(ITT analysis) still febrile through time by treatment group.doi:10.1371/journal.pone.0002188.g003Treatment of Typhoid Fever\nPLoS ONE | www.plosone.org 7 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 0, "end_char_idx": 1157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "376f39d4-26b9-4d04-b712-4aefcef2eb04": {"__data__": {"id_": "376f39d4-26b9-4d04-b712-4aefcef2eb04", "embedding": null, "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f8637173-d655-4302-99f4-08a15b391843", "node_type": "4", "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "f0a3460ccb81ec4f55580fe2c2930ca41d911d7cd2c109f6680131ff8fa2b1b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4baef134-5231-4b7d-b791-c9a9196988c9", "node_type": "1", "metadata": {"page_label": "7", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "719c55fc235e5488495b3dc958f4d4967a3f00aceaa3d35172d76b62eb674516", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66ea171e-5d2b-4eea-86df-6d8d4bac46e6", "node_type": "1", "metadata": {}, "hash": "0dc8380c9c70957b91edeca24cde3385f802ae7cd2859d6b371efcc8c9dc26f7", "class_name": "RelatedNodeInfo"}}, "text": "Adverse events\nBoth treatments were well tolerated. One adverse event related\nto azithromycin was reported, a maculopapular rash that occurredafter the first dose of treatment. Azithromycin was discontinued\nimmediately and the patient was treated with ceftriaxone.\nGastrointestinal side-effects (change in consistency and frequen-\ncy of stools) that were probably typhoid fever related were\nrelatively frequent in both treatment arms at the start of treatment.In the gatifloxacin group, one patient experienced vomiting on day\n2 and day 3 and one patient diarrhoea (4 episodes/day) on day 4\nand day 5 of treatment. These episodes were self-limiting and did\nnot require the interruption of therapy.\nThe median levels of serum AST and ALT fell in both groups\nafter 7 days of therapy. In the PP group, the median post-\ntreatment AST was 46.35 U/L (range 12.8\u2013217.5) in the\ngatifloxacin arm and 45 U/L (range 5\u2013358) in the azithromycin\narm. The median post-treatment ALT fell to 46.8 U/L (range\n7.4\u2013278) and 49.9 (1.1\u2013494), respectively. In the culture-negativepatients, the median post-treatment AST was 44.8 U/L (range\n12\u2013654) and ALT was 40 U/L (range 10\u2013424.4).\nAntimicrobial susceptibilities of S. typhi and S. paratyphi\nA isolates\nFrom the PP population, 282 (98%) S. typhi and 5 (2%) S.\nparatyphi A strains were isolated.", "start_char_idx": 0, "end_char_idx": 1324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66ea171e-5d2b-4eea-86df-6d8d4bac46e6": {"__data__": {"id_": "66ea171e-5d2b-4eea-86df-6d8d4bac46e6", "embedding": null, "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f8637173-d655-4302-99f4-08a15b391843", "node_type": "4", "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "f0a3460ccb81ec4f55580fe2c2930ca41d911d7cd2c109f6680131ff8fa2b1b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "376f39d4-26b9-4d04-b712-4aefcef2eb04", "node_type": "1", "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "55f5b05bbf6aac6b825c02f64eb7d8b45bf52a3bb85e72f40a05df77f0722c9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76bfb191-ba8e-42d9-ae10-882c82d52fe3", "node_type": "1", "metadata": {}, "hash": "b122c38c2b22cf1cd645a5086cf92e585dab688306af49c71142aed58308f938", "class_name": "RelatedNodeInfo"}}, "text": "Two hundred and sixty three S.\ntyphiand 5 S. paratyphi A were received at the Hospital for Tropical\nDiseases for antimicrobial susceptibility testing.\nFifty-eight percent of the S. typhi isolates were MDR and 96%\nwere nalidixic acid resistant and showed reduced susceptibility tothe older generation fluoroquinolones (Table 3). However\ntechnically, using current CLSI breakpoints, all isolates remained\nsusceptible in vitro to ciprofloxacin and ofloxacin. The MIC\n90of\ngatifloxacin was the lowest of all the fluoroquinolones tested at0.19mg/mL (range 0.004\u20130.5). All isolates were susceptible to\nceftriaxone.\nThe 5 S. paratyphi A strains were fully susceptible to all the\nantimicrobials tested.\nDiscussion\nInterpretation\nThe results of this trial show that both antibiotics worked well\nfor the treatment of MDR and nalidixic acid resistant typhoid\nfever in Vietnam. A seven day oral course of gatifloxacin had\nsimilar efficacy and safety as a seven day course of azithromycin,\nwhich is recommended for the treatment of MDR and nalidixic\nacid resistant typhoid fever [7,9].\nHowever, azithromycin is not available throughout much of the\ndeveloping world and it is expensive. The costs of a 7-day\ntreatment course of gatifloxacin (at 10 mg/kg/day) for an adult\npatient in Vietnam are approximately 25 US$, the costs of\nazithromycin (at 20 mg/kg/day) are more than 90 US$.", "start_char_idx": 1325, "end_char_idx": 2693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76bfb191-ba8e-42d9-ae10-882c82d52fe3": {"__data__": {"id_": "76bfb191-ba8e-42d9-ae10-882c82d52fe3", "embedding": null, "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f8637173-d655-4302-99f4-08a15b391843", "node_type": "4", "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "f0a3460ccb81ec4f55580fe2c2930ca41d911d7cd2c109f6680131ff8fa2b1b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66ea171e-5d2b-4eea-86df-6d8d4bac46e6", "node_type": "1", "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "657809032ee32fa4d9730bafb4afaaa0bb26e91e5b95bc57763257f30c9cad96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96bb9068-a533-4f57-944e-789e4f86ccbf", "node_type": "1", "metadata": {}, "hash": "dbe316fa13d6660d8246efa583908c85abab776aa0c725491d9584e89e9b2fc4", "class_name": "RelatedNodeInfo"}}, "text": "The results for gatifloxacin in this trial are comparable to the\nexcellent clinical outcomes achieved with ofloxacin in Vietnam in\nthe early 1990s, when S. typhi isolates were still susceptible to\nnalidixic acid [17\u201319].\nGatifloxacin has a higher affinity to GyrA and is less inhibited\nby the common mutations in the GyrA gene [20]. The gatifloxacin\nMIC 50of the study isolates was 0.19 mg/mL compared to the\noxfloxacin MIC 50of 0.75 mg/mL. We would not recommend the\ncontinued use of the older generation fluoroquinolones (ofloxacin\nand ciprofloxacin) in regions with high rates of nalidixic acid\nresistant typhoid fever for fear of selecting further mutations in\ngyrA[21]. This could put at risk the potential clinical benefit of the\nnewer fluoroquinolones, including gatifloxacin.\nThere have been several case reports of gatifloxacin-associated\ndysglycemia in patients with type II diabetes mellitus, overweight\nFigure 4. Proportion of patients with overall failure in the culture confirmed population. Kaplan-Meier survival curve showing the\nproportion of patients with overall failure in the culture confirmed population (PP analysis) by treatment group.\ndoi:10.1371/journal.pone.0002188.g004Treatment of Typhoid Fever\nPLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 2694, "end_char_idx": 3984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96bb9068-a533-4f57-944e-789e4f86ccbf": {"__data__": {"id_": "96bb9068-a533-4f57-944e-789e4f86ccbf", "embedding": null, "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "04550f71-d7cc-499f-80ba-93ab50274415", "node_type": "4", "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "f6046fc59459f36c0e677d780a467663a81f7ce000c1466544942b67e365c07a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76bfb191-ba8e-42d9-ae10-882c82d52fe3", "node_type": "1", "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "e78e5368365c241deb8ec59a92b676bfb8740b495ef7fa6245055f7f8177c293", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05d3d67a-dc2e-4244-8ba8-a085e580a36a", "node_type": "1", "metadata": {}, "hash": "7237f5c80792da20c6a8f256e6c77494cb07ce03c2d53f3c979241cf226abaa6", "class_name": "RelatedNodeInfo"}}, "text": "or with other comorbidity [22\u201324]. Recently there have been\nconcerns about the use of gatifloxacin, after a retrospective case-control study in 1.4 million individuals over the age of 66 years(mean age 77 years) in Canada was published [25].\nAs our trial was completed before publication of this report, we\ndid not systematically monitor for hypo- and hyperglycemia.Blood glucose levels taken as part of the routine care were normal.All patients were managed as in-patients and potential symptomsof hypo- and hyperglycemia would have been noted by the studyphysicians. No dysglycemia events were reported during the in-patient period or during the follow up period of 3 to 6 months.\nThe patients in our trial were healthy, young and non-obese\nindividuals. A trial in 867 children with otitis media with glucosemonitoring and a one year follow-up [26], as well as a recententeric (typhoid and paratyphoid) fever trial in Nepal usedgatifloxacin and did not report any dysglycemia [10]. In oursetting and in our patient population gatifloxacin was highlyeffective despite very high rates of drug resistance and was welltolerated.\nOther newer generation fluoroquinolones, i.e. gemifloxacin and\nmoxifloxacin have shown low MICs for nalidixic acid resistant S.\ntyphi and S. paratyphi A [11], unfortunately these drugs are not\navailable in Vietnam and they are considerably more expensive.The in vitro results seen with these other newer generationfluoroquinolones should be evaluated in clinical trials.", "start_char_idx": 0, "end_char_idx": 1497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05d3d67a-dc2e-4244-8ba8-a085e580a36a": {"__data__": {"id_": "05d3d67a-dc2e-4244-8ba8-a085e580a36a", "embedding": null, "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "04550f71-d7cc-499f-80ba-93ab50274415", "node_type": "4", "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "f6046fc59459f36c0e677d780a467663a81f7ce000c1466544942b67e365c07a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96bb9068-a533-4f57-944e-789e4f86ccbf", "node_type": "1", "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "a8a19defc2b3786f7ef18a762b13ee8b3c227c2f4e012dcd40ec16a9ddd022ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4225121b-5670-4f9d-ba79-8cabaab22aae", "node_type": "1", "metadata": {}, "hash": "e49222450c51373b911986aa7eeeb0ba9ef3b7c3089d80d8e71fbe378033b622", "class_name": "RelatedNodeInfo"}}, "text": "Generalizability\nThe emergence of nalidixic acid resistant S. typhi and S. paratyphi\nA with reduced susceptibility to the fluoroquinolones is awidespread problem throughout Asia and therefore our study isrelevant to the whole region [2,6]. Many case reports and somerandomised controlled trials have described the worsening clinicalresponse to ciprofloxacin and ofloxacin [8,27,28].The search for effective antibiotics to treat typhoid fever is\nimperative.\nTypically trials in typhoid fever are limited by small sample\nsizes, a recent Cochrane Report has stressed the need for large\nwell-designed trials in enteric fever [29]. The evidence from our\ntrial is strengthened by a sample size of 287 patients with cultureconfirmed typhoid fever (358 patients randomised), which we\nbelieve is so far the largest RCT performed in typhoid fever.\nBoth antibiotics also worked well for the patients with negative\nblood cultures. This is an important finding because the sensitivity\nof blood culture for the diagnosis of typhoid fever is only\napproximately 50 to 80% [9].\nLimitations of the study\nThe randomisation sequence was generated with a large block\nsize of 50, which resulted in uneven numbers in the two treatment\ngroups (186 versus 172 patients in the ITT population).\nOne possible limitation was the low rate of stool cultures positive\nforS. typhi. Faecal carriage is usually characterised by intermittent\nshedding and the stool culture for S. typhi is not very sensitive.", "start_char_idx": 1498, "end_char_idx": 2970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4225121b-5670-4f9d-ba79-8cabaab22aae": {"__data__": {"id_": "4225121b-5670-4f9d-ba79-8cabaab22aae", "embedding": null, "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "04550f71-d7cc-499f-80ba-93ab50274415", "node_type": "4", "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "f6046fc59459f36c0e677d780a467663a81f7ce000c1466544942b67e365c07a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05d3d67a-dc2e-4244-8ba8-a085e580a36a", "node_type": "1", "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "3db9f95a9c1f35ab857b52817ba23e0df10431d388aa935876b9a7e458c12195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa439f02-2fb8-4cde-9f3a-925915c77764", "node_type": "1", "metadata": {}, "hash": "98c4741420c9095ee7b01bd22f9d7ba49e250e4f7292d391afc5670a543b512d", "class_name": "RelatedNodeInfo"}}, "text": "One possible limitation was the low rate of stool cultures positive\nforS. typhi. Faecal carriage is usually characterised by intermittent\nshedding and the stool culture for S. typhi is not very sensitive.\nWhen comparing our data with other studies that demonstrate\nthat azithromycin is highly efficacious for the treatment of typhoidfever, we find similar low rates of faecal carriage at follow-up\n[7,30]. It could be hypothesized that antibiotics that show high\nintracellular concentrations and good tissue penetration like\nazithromycin and the fluoroquinolones, achieve rapid bacterial\nkilling and elimination throughout the body, which reduces faecal\ncarriage.\nThe dose of gatifloxacin and azithromycin tablets was prepared\nby careful cutting of the tablets (proportions of the tablets\nadministered were recorded in the CRFs). Inevitably, it was\ntherefore an estimation of the exact dose, hence we cannot\nguarantee that each patient received exactly 10 mg/kg/day ofgatifloxacin or 20 mg/kg/day of azithromycin.\nFigure 5. Proportion of patients with relapse in the culture confirmed population. Kaplan-Meier survival curve showing the proportion of\npatients with relapse in the culture confirmed population (PP analysis) by treatment group.\ndoi:10.1371/journal.pone.0002188.g005Treatment of Typhoid Fever\nPLoS ONE | www.plosone.org 9 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 2766, "end_char_idx": 4139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa439f02-2fb8-4cde-9f3a-925915c77764": {"__data__": {"id_": "fa439f02-2fb8-4cde-9f3a-925915c77764", "embedding": null, "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "77ef7725da711affe7301ef3f3212d4593895828b4fab70af748c9520bb47c0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4225121b-5670-4f9d-ba79-8cabaab22aae", "node_type": "1", "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "3422c77f665acdc479f8cf9542cf57da2d47845113e64dee0de32293fc6f37f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f2fd2c9-1cf0-402c-8d06-05fe6d436770", "node_type": "1", "metadata": {}, "hash": "a66bd4cecad45e86d6a524d1bd90153fbb2bc6d9b5ce75169ea819d4dbdfe8ee", "class_name": "RelatedNodeInfo"}}, "text": "Overall evidence. We performed a MEDLINE search for\n\u2018\u2018azithromycin, clinical trial, typhoid/enteric fever\u2019\u2019 and used therecent enteric fever Cochrane report [29] to identify 6 clinicaltrials in the literature. In total, 251 typhoid fever patients weretreated with azithromycin.\nFour trials, three from Egypt and one from India, used\nazithromycin to treat MDR typhoid fever [30\u201333]. Azithromycinachieved cure rates between 88% and 100%, the mean FCTranged from 3.8 to 4.5 days. Two trials performed in Vietnamused azithromycin at 20 mg/kg/day [7] and at 10 mg/kg/day [8]\nfor the treatment of MDR and nalidixic acid resistant typhoid\nfever. In total, 107 patients with culture confirmed typhoid feverwere enrolled. The cure rate was 93% and 82% and the FCT was5.6 and 5.8 days, respectively. Our results concur with theseexcellent data .\nA recent trial conducted in Kathmandu, Nepal used gatifloxacin\nat the same dose and duration for the treatment of nalidixic acidresistant typhoid fever [10]. Successful treatment was achieved in96.5% (85 out of 88) patients and the median FCT (95% CI) was92 hours (84\u2013114 hours). The trial in Nepal was stopped early bythe independent Data and Safety Monitoring Committee as a\nresult of the poor clinical response in the patients randomised tocefixime.", "start_char_idx": 0, "end_char_idx": 1288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f2fd2c9-1cf0-402c-8d06-05fe6d436770": {"__data__": {"id_": "9f2fd2c9-1cf0-402c-8d06-05fe6d436770", "embedding": null, "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "77ef7725da711affe7301ef3f3212d4593895828b4fab70af748c9520bb47c0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa439f02-2fb8-4cde-9f3a-925915c77764", "node_type": "1", "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "e48a2e9a2b34fd222f14e7cdd91407cb808997d44a299144b94eddc1fe50bfba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ca96715-541d-475a-961e-1c769e48cf70", "node_type": "1", "metadata": {}, "hash": "5b801819ede943ff9804d18ef585ca41861e14d45225650ed3ee8c59659cd063", "class_name": "RelatedNodeInfo"}}, "text": "The trial in Nepal was stopped early bythe independent Data and Safety Monitoring Committee as a\nresult of the poor clinical response in the patients randomised tocefixime.\nWe believe on the basis of this and other recently published\ntrials, that gatifloxacin or azithromycin are now the treatments ofchoice for enteric fever in areas of MDR and nalidixic acidresistance [7,8,10]. However it is important to use theseantimicrobial agents cautiously because indiscriminate use wouldinevitably induce further resistance.\nSupporting Information\nProtocol S1 Trial Protocol\nFound at: doi:10.1371/journal.pone.0002188.s001 (0.07 MB\nDOC)\nChecklist S1 CONSORT Checklist\nFound at: doi:10.1371/journal.pone.0002188.s002 (0.06 MB\nDOC)Table 3. Antimicrobial susceptibilities and minimum inhibitory concentrations (MIC) of 263 S. typhi isolate.\nTreatment with\nAll isolates Gatifloxacin Azithromycin\nn = 263 n = 137 n = 126\nMultidrug resistant, numbers (%) 153 (58) 87 (63.5) 66 (52.3)\nNalidixic acid resistant, numbers (%) 254 (96.5) 132 (96.3) 121 (96)\nMIC 50 ( mg/ml) .256 .256 .256\nAmoxicillin MIC 90 ( mg/ml) .256 .256 .256\nrange ( mg/ml) 0.125 to .256 0.5 to .256 0.125 to .256\nMIC 50 ( mg/ml) .256 .256 .256\nChloramphenicol MIC 90 ( mg/ml) .", "start_char_idx": 1116, "end_char_idx": 2350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ca96715-541d-475a-961e-1c769e48cf70": {"__data__": {"id_": "5ca96715-541d-475a-961e-1c769e48cf70", "embedding": null, "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "77ef7725da711affe7301ef3f3212d4593895828b4fab70af748c9520bb47c0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f2fd2c9-1cf0-402c-8d06-05fe6d436770", "node_type": "1", "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "a94cabdbed902ec08d63ef98e8e80e6f33540f1d30252bdfce63377039eec437", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93abe397-b96e-4846-bc48-5c242f3a8ce0", "node_type": "1", "metadata": {}, "hash": "d95610ac3eceee45ac8c511f455d0b0b2f2161e9d67fa92977c61a6f9dede429", "class_name": "RelatedNodeInfo"}}, "text": "125 to .256 0.5 to .256 0.125 to .256\nMIC 50 ( mg/ml) .256 .256 .256\nChloramphenicol MIC 90 ( mg/ml) .256 .256 .256\nrange ( mg/ml) 0.38 to .256 2 to .256 0.38 to .256\nMIC 50 ( mg/ml) .256 .256 .256\nNalidixic acid MIC 90 ( mg/ml) .256 .256 .256\nrange ( mg/ml) 1.5 to .256 1.5 to .256 1.5 to .256\nMIC 50 ( mg/ml) 0.75 0.75 1\nOfloxacin MIC 90 ( mg/ml) 1.5 1.5 1.5\nrange ( mg/ml) 0.023\u20132 0.032\u20132 0.023\u20132\nMIC 50 ( mg/ml) 0.38 0.38 0.38\nCiprofloxacin MIC 90 ( mg/ml) 0.5 0.5 0.5\nrange ( mg/ml) 0.004\u20130.75 0.006\u20130.75 0.004\u20130.38\nMIC 50 ( mg/ml) 0.125 0.125 0.125\nGatifloxacin MIC 90 ( mg/ml) 0.19 0.19 0.19\nrange ( mg/ml) 0.004\u20130.5 0.006\u20130.25 0.004\u20130.5\nMIC 50 ( mg/ml) 0.125 0.125 0.", "start_char_idx": 2248, "end_char_idx": 2923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93abe397-b96e-4846-bc48-5c242f3a8ce0": {"__data__": {"id_": "93abe397-b96e-4846-bc48-5c242f3a8ce0", "embedding": null, "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a", "node_type": "4", "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "77ef7725da711affe7301ef3f3212d4593895828b4fab70af748c9520bb47c0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ca96715-541d-475a-961e-1c769e48cf70", "node_type": "1", "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "1e5d10ef4fdf148c483c98b7ddb9010466da0e523d0507dfa3133ae84c2a4ab3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ab98b7d-a216-4fbb-83f3-87448af1fabd", "node_type": "1", "metadata": {}, "hash": "cb2e07c8db345db362be0f2cde7b62a3068017908cac86a275a7df3a17b95041", "class_name": "RelatedNodeInfo"}}, "text": "19\nrange ( mg/ml) 0.004\u20130.5 0.006\u20130.25 0.004\u20130.5\nMIC 50 ( mg/ml) 0.125 0.125 0.125\nCeftriaxone MIC 90 ( mg/ml) 0.125 0.125 0.19\nrange ( mg/ml) 0.064\u20130.25 0.064\u20130.19 0.064\u20130.25\nMIC 50 ( mg/ml) 8 8 8\nAzithromycin MIC 90 ( mg/ml) 12 12 12\nrange ( mg/ml) 1.5\u201316 1.5\u201316 4\u201316\nMIC 50/90, concentration at which 50% and 90% of the organisms respectively are inhibited. MDR is defined as resistance to chloramphenicol, ampicillin and\ntrimethoprim-sulfamethoxazole. CLSI MIC breakpoints are as follows: for chloramphenicol, ampicillin and nalidixic acid resistance $32mg/mL; ofloxacin and gatifloxacin\n#2mg/mL susceptible and $8mg/mL resistant; ciprofloxacin #1mg/mL susceptible and $4mg/mL resistant; ceftriaxone #8mg/mL susceptible and $64mg/mL\nresistant; there are none for azithromycin.doi:10.1371/journal.pone.0002188.t003Treatment of Typhoid Fever\nPLoS ONE | www.plosone.org 10 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 2844, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ab98b7d-a216-4fbb-83f3-87448af1fabd": {"__data__": {"id_": "1ab98b7d-a216-4fbb-83f3-87448af1fabd", "embedding": null, "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d9a118-1636-480d-b21d-3ee904356b85", "node_type": "4", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "11955eaf648c2510b85ed6f45650b1af54bf603be61697288c216e99c52dfbed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93abe397-b96e-4846-bc48-5c242f3a8ce0", "node_type": "1", "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "bc8731e4f6bc26dbd97158927e14ac8f06e92c2691dfa496c82cf81144f89842", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bd9101c-408e-4dfc-b6b5-e00afa197afc", "node_type": "1", "metadata": {}, "hash": "55a0d83e9541d3ba4fa26c478d715b5f0e23bad9774c048f409953e0b071bb3a", "class_name": "RelatedNodeInfo"}}, "text": "Acknowledgments\nWe are grateful to all the doctors and nurses who cared for the patients in\nthis study and to all the patients and their relatives. We wish to thank themembers of the Data and Safety Monitoring Board, Dr. Christopher M.Parry, Liverpool University, UK and Professor Nicholas J. White, MahidolUniversity, Bangkok, Thailand.Author Contributions\nConceived and designed the experiments: TH JF SD PT NS NC KS CD\nBB JC TS NV TP NR LP HV DD NB ML PB VH CS. Performed the\nexperiments: TH JF SD NS NC CD JC TS NV TP NR LP HV DD NB\nDL LH NB NH PD ML PB VH NH TN TC CS. Analyzed the data: THJF PT NS NC KS CD NV TP NR LP HV. Wrote the paper: TH JF PT\nNS NC KS CD NV TP NR LP HV.\nReferences\n1. Crump JA, Luby SP, Mintz ED (2004) The global burden of typhoid fever. Bull\nWorld Health Organ 82: 346\u2013353.\n2. Bhan MK, Bahl R, Bhatnagar S (2005) Typhoid and paratyphoid fever. Lancet\n366: 749\u2013762.\n3. Bhutta ZA (2006) Current concepts in the diagnosis and treatment of typhoid\nfever. Bmj 333: 78\u201382.\n4. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ (2002) Typhoid fever.\nN Engl J Med 347: 1770\u20131782.\n5.", "start_char_idx": 0, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bd9101c-408e-4dfc-b6b5-e00afa197afc": {"__data__": {"id_": "0bd9101c-408e-4dfc-b6b5-e00afa197afc", "embedding": null, "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d9a118-1636-480d-b21d-3ee904356b85", "node_type": "4", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "11955eaf648c2510b85ed6f45650b1af54bf603be61697288c216e99c52dfbed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ab98b7d-a216-4fbb-83f3-87448af1fabd", "node_type": "1", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "25a632aaa5af8e8c1991e7e286491807bbd5eac07ccbfd3570997bc69c8f3f39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22052704-67af-4bad-9e7e-691830cbce6e", "node_type": "1", "metadata": {}, "hash": "13ffe10de832997ef6a0ab246e56bd5ff1acb50e4c14db593f9167bdef30e970", "class_name": "RelatedNodeInfo"}}, "text": "4. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ (2002) Typhoid fever.\nN Engl J Med 347: 1770\u20131782.\n5. Nguyen TA, Ha Ba K, Nguyen TD (1993) [Typhoid fever in South Vietnam,\n1990\u20131993]. Bull Soc Pathol Exot 86: 476\u2013478.\n6. Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, et al.\n(2007) Antimicrobial drug resistance of Salmonella enterica serovar Typhi in Asia\nand molecular mechanism of reduced susceptibility to the fluoroquinolones.\nAntimicrob Agents Chemother 51: 4315\u20134323.\n7. Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, et al. (2000) A randomized\ncontrolled comparison of azithromycin and ofloxacin for treatment of multidrug-\nresistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother\n44: 1855\u20131859.\n8. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, et al. (2007) Randomized\ncontrolled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromy-\ncin combination for treatment of multidrug-resistant and nalidixic acid-resistant\ntyphoid fever. Antimicrob Agents Chemother 51: 819\u2013825.\n9. WHO (2003) Backgound document: The diagnosis, treatment and prevention of\ntyphoid fever.", "start_char_idx": 998, "end_char_idx": 2123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22052704-67af-4bad-9e7e-691830cbce6e": {"__data__": {"id_": "22052704-67af-4bad-9e7e-691830cbce6e", "embedding": null, "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d9a118-1636-480d-b21d-3ee904356b85", "node_type": "4", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "11955eaf648c2510b85ed6f45650b1af54bf603be61697288c216e99c52dfbed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bd9101c-408e-4dfc-b6b5-e00afa197afc", "node_type": "1", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "6a0b13c33785f11a7362cbb992c0953e942a416db5f67ef367d6a5e84da4b8b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85453251-171a-4b92-9525-90761c071881", "node_type": "1", "metadata": {}, "hash": "50c5956329c87ac3f00fbe4ae5594436dec91be029d05482115885027bc2fbe4", "class_name": "RelatedNodeInfo"}}, "text": "Antimicrob Agents Chemother 51: 819\u2013825.\n9. WHO (2003) Backgound document: The diagnosis, treatment and prevention of\ntyphoid fever. Department of Vaccines and Biologicals - World HealthOrganization. http://www.who.int/vaccine_research/documents/en/typhoid_\ndiagnosis.pdf.\n10. Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, et al. (2007) An open\nrandomized comparison of gatifloxacin versus cefixime for the treatment of\nuncomplicated enteric fever. PLoS ONE 2: e542.\n11. Maskey AP, Day JN, Phung QT, Thwaites GE, Campbell JI, et al. (2006)\nSalmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause\nindistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 42:\n1247\u20131253.\n12. Clinical and Laboratory Standard Institute (2006) Performance standards for\nantimicrobial susceptibility tests. Approved standard, 9th ed. CLSI document\nM2-A9. CLSI, Pennsylvania, USA.\n13. Clinical and Laboratory Standard Institute (2007) Performance standards for\nantimicrobial susceptibility testing; seventeenth informational supplement.\nMS100-S17. CLSI, Pennsylvania, USA.\n14. Machin D, Campbell MJ, Fayers PM, Pinol APY (1997) Sample size tables for\nthe design of clinical trials (2nd edition). Oxford: Blackwell Science.\n15.", "start_char_idx": 1991, "end_char_idx": 3233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85453251-171a-4b92-9525-90761c071881": {"__data__": {"id_": "85453251-171a-4b92-9525-90761c071881", "embedding": null, "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d9a118-1636-480d-b21d-3ee904356b85", "node_type": "4", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "11955eaf648c2510b85ed6f45650b1af54bf603be61697288c216e99c52dfbed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22052704-67af-4bad-9e7e-691830cbce6e", "node_type": "1", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "2292459543e50e8864e249ce15eb57a356ee8ec08a2a8fe99cd7d590af0a979b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc49b8da-9c07-44e8-8990-3e0258691387", "node_type": "1", "metadata": {}, "hash": "b4a96ddbb6bcdbdb640ec6a4c93c9480eb065cef3a1289fbd6134c44ea27428b", "class_name": "RelatedNodeInfo"}}, "text": "14. Machin D, Campbell MJ, Fayers PM, Pinol APY (1997) Sample size tables for\nthe design of clinical trials (2nd edition). Oxford: Blackwell Science.\n15. Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume 1 -\nThe analysis of case-control studies. Lyon: International Agency for Research on\nCancer.\n16. Collett D (2003) Modelling survival data in medical research (2nd edition). Boca\nRaton: CRC Press.\n17. Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, et al. (1999) A\ncomparative study of ofloxacin and cefixime for treatment of typhoid fever inchildren. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr Infect\nDis J 18: 245\u2013248.18. Tran TH, Bethell DB, Nguyen TT, Wain J, To SD, et al. (1995) Short course of\nofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 20:917\u2013923.\n19. Vinh H, Wain J, Vo TN, Cao NN, Mai TC, et al. (1996) Two or three days of\nofloxacin treatment for uncomplicated multidrug-resistant typhoid fever inchildren. Antimicrob Agents Chemother 40: 958\u2013961.\n20.", "start_char_idx": 3080, "end_char_idx": 4114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc49b8da-9c07-44e8-8990-3e0258691387": {"__data__": {"id_": "fc49b8da-9c07-44e8-8990-3e0258691387", "embedding": null, "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d9a118-1636-480d-b21d-3ee904356b85", "node_type": "4", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "11955eaf648c2510b85ed6f45650b1af54bf603be61697288c216e99c52dfbed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85453251-171a-4b92-9525-90761c071881", "node_type": "1", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "30f5706dbafb2d97ed6946a4ca32b7e9de28489ef3c28d0a4365b50c913cf213", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ce9a047-d444-4362-9486-37cb9d3aeb7e", "node_type": "1", "metadata": {}, "hash": "a1a4e4f62fc617ba85a5073edc73398b7e54631801790823af7a38e0f5f5e36d", "class_name": "RelatedNodeInfo"}}, "text": "(1996) Two or three days of\nofloxacin treatment for uncomplicated multidrug-resistant typhoid fever inchildren. Antimicrob Agents Chemother 40: 958\u2013961.\n20. Lu T, Zhao X, Drlica K (1999) Gatifloxacin activity against quinolone-resistant\ngyrase: allele-specific enhancement of bacteriostatic and bactericidal activities bythe C-8-methoxy group. Antimicrob Agents Chemother 43: 2969\u20132974.\n21. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL (2007) The relationship\nbetween quinolone exposures and resistance amplification is characterized by aninverted U: a new paradigm for optimizing pharmacodynamics to counterselectresistance. Antimicrob Agents Chemother 51: 744\u2013747.\n22. Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH (2003)\nGatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a\npotential age-related dose reduction. J Antimicrob Chemother 52: 435\u2013440.\n23. Baker SE, Hangii MC (2002) Possible gatifloxacin-induced hypoglycemia. Ann\nPharmacother 36: 1722\u20131726.\n24. Frothingham R (2005) Glucose homeostasis abnormalities associated with use of\ngatifloxacin. Clin Infect Dis 41: 1269\u20131276.\n25. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, et al.", "start_char_idx": 3958, "end_char_idx": 5154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ce9a047-d444-4362-9486-37cb9d3aeb7e": {"__data__": {"id_": "6ce9a047-d444-4362-9486-37cb9d3aeb7e", "embedding": null, "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d9a118-1636-480d-b21d-3ee904356b85", "node_type": "4", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "11955eaf648c2510b85ed6f45650b1af54bf603be61697288c216e99c52dfbed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc49b8da-9c07-44e8-8990-3e0258691387", "node_type": "1", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "55dc366f38ef64df429b33b12ca51bf72aea6c5001bf5208d40b5b124040f73e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33bb6070-7027-4e5e-b95e-555b18ee5bda", "node_type": "1", "metadata": {}, "hash": "65d7247315c7da78162b9db9bad5319cbdc45f589af0e2eb3d7ed1ce54fe80da", "class_name": "RelatedNodeInfo"}}, "text": "Clin Infect Dis 41: 1269\u20131276.\n25. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, et al. (2006)\nOutpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med354: 1352\u20131361.\n26. Pichichero ME, Arguedas A, Dagan R, Sher L, Saez-Llorens X, et al. (2005)\nSafety and efficacy of gatifloxacin therapy for children with recurrent acute otitis\nmedia (AOM) and/or AOM treatment failure. Clin Infect Dis 41: 470\u2013478.\n27. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ (2003) Is it time to change\nfluoroquinolone breakpoints for Salmonella spp .? Antimicrob Agents Chemother\n47: 827\u2013829.\n28. Kadhiravan T, Wig N, Kapil A, Kabra SK, Renuka K, et al. (2005) Clinical\noutcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi . BMC Infect Dis 5: 37.\n29. Thaver D, Zaidi AK, Critchley J, Madni SA, Bhutta ZA (2005) Fluoroquin-\nolones for treating typhoid and paratyphoid fever (enteric fever). CochraneDatabase Syst Rev: CD004530.\n30. Frenck RW Jr, Mansour A, Nakhla I, Sultan Y, Putnam S, et al.", "start_char_idx": 5056, "end_char_idx": 6106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33bb6070-7027-4e5e-b95e-555b18ee5bda": {"__data__": {"id_": "33bb6070-7027-4e5e-b95e-555b18ee5bda", "embedding": null, "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06d9a118-1636-480d-b21d-3ee904356b85", "node_type": "4", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "11955eaf648c2510b85ed6f45650b1af54bf603be61697288c216e99c52dfbed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ce9a047-d444-4362-9486-37cb9d3aeb7e", "node_type": "1", "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}, "hash": "df9651b63c3a4c675934d96933dfb3df0db7dc49908c6ab6f00355a07f888be8", "class_name": "RelatedNodeInfo"}}, "text": "CochraneDatabase Syst Rev: CD004530.\n30. Frenck RW Jr, Mansour A, Nakhla I, Sultan Y, Putnam S, et al. (2004) Short-\ncourse azithromycin for the treatment of uncomplicated typhoid fever inchildren and adolescents. Clin Infect Dis 38: 951\u2013957.\n31. Butler T, Sridhar CB, Daga MK, Pathak K, Pandit RB, et al. (1999) Treatment\nof typhoid fever with azithromycin versus chloramphenicol in a randomizedmulticentre trial in India. J Antimicrob Chemother 44: 243\u2013250.\n32. Frenck RW Jr, Nakhla I, Sultan Y, Bassily SB, Girgis YF, et al. (2000)\nAzithromycin versus ceftriaxone for the treatment of uncomplicated typhoid\nfever in children. Clin Infect Dis 31: 1134\u20131138.\n33. Girgis NI, Butler T, Frenck RW, Sultan Y, Brown FM, et al. (1999)\nAzithromycin versus ciprofloxacin for treatment of uncomplicated typhoid feverin a randomized trial in Egypt that included patients with multidrug resistance.Antimicrob Agents Chemother 43: 1441\u20131444.Treatment of Typhoid Fever\nPLoS ONE | www.plosone.org 11 May 2008 | Volume 3 | Issue 5 | e2188", "start_char_idx": 6004, "end_char_idx": 7028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"bfc8d877-35fe-44fc-8eef-eb400919f219": {"node_ids": ["2f39b3a8-7107-4bbf-a70a-806d8262427b", "422a4fa0-f439-44d3-b69f-7605a774538e", "6e108435-e3a2-45db-9cac-40fde64aee65", "a1ddabdd-d2ee-4d53-b0b8-08963da293bb", "ff9c8508-0b28-4ab0-8f5a-f8e7f349c8e1"], "metadata": {"page_label": "1", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "672a39ab-7a7b-4663-acfc-5275cf133ba1": {"node_ids": ["fa5c19bf-fc62-4fb2-a295-8e97b2140023", "40223ddf-cd72-4d04-80e9-313875f9246e", "183b296c-ed4d-4070-8252-25568fbc2eae", "f71fe3d0-a17e-420f-830a-5501ace567b3", "87029fc9-73d8-4fd0-93a4-c84944fba0c9"], "metadata": {"page_label": "2", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "06d85b90-bd53-462a-a8e3-d8178e418217": {"node_ids": ["d7a5ac4b-9026-4335-bf63-1f522999e1d6", "0c506829-03c3-4e6f-b38a-0d1e52127ff2", "8716d68a-85f5-4cea-a2bf-c866d40291fb", "f96b4c1c-1a97-4e92-b582-082ea78bdaba", "e753db88-bc85-46f5-9f8d-1029109515e5", "9e508ff4-a59a-4527-b3f0-c57ab152f418"], "metadata": {"page_label": "3", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "bf3c95e5-c8a7-4512-a7f6-f49242c241b9": {"node_ids": ["a38d1522-b9c0-4b43-87ec-a72cc00f6784", "d92ca9cf-dfef-45e0-940e-ca3bd23ad6d9", "c677c62b-7286-4c54-bb71-fcdbdb60e215", "937ff68d-1aa4-46a3-a630-9a2eefdf0784", "cfb884ef-e5c0-48e9-b011-4b40eacd5d32", "6216f214-1228-4ee3-8cbe-12685d7d54f0"], "metadata": {"page_label": "4", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "0db985ec-628a-488b-8fb9-661208994002": {"node_ids": ["927c24b9-a4be-4434-9fcd-ce85f082d353"], "metadata": {"page_label": "5", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "609f90f6-301f-406c-981c-d012a6b828f2": {"node_ids": ["05925efc-e111-4144-ba67-997207668dff", "cb226240-ce85-4610-9086-342a37977f38", "7faa8a9f-e98b-4db7-bfe5-e8ac416c6810", "e0aaac66-3403-4944-b48c-6a36ed80f016", "ed7f2783-2b31-48ad-9c5c-33816b54fd1c"], "metadata": {"page_label": "6", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "7beec391-5b20-4fb3-9abc-41419b5d295f": {"node_ids": ["4baef134-5231-4b7d-b791-c9a9196988c9"], "metadata": {"page_label": "7", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "f8637173-d655-4302-99f4-08a15b391843": {"node_ids": ["376f39d4-26b9-4d04-b712-4aefcef2eb04", "66ea171e-5d2b-4eea-86df-6d8d4bac46e6", "76bfb191-ba8e-42d9-ae10-882c82d52fe3"], "metadata": {"page_label": "8", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "04550f71-d7cc-499f-80ba-93ab50274415": {"node_ids": ["96bb9068-a533-4f57-944e-789e4f86ccbf", "05d3d67a-dc2e-4244-8ba8-a085e580a36a", "4225121b-5670-4f9d-ba79-8cabaab22aae"], "metadata": {"page_label": "9", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "6c6aa6a6-a9aa-4755-8ee5-af26ccc8412a": {"node_ids": ["fa439f02-2fb8-4cde-9f3a-925915c77764", "9f2fd2c9-1cf0-402c-8d06-05fe6d436770", "5ca96715-541d-475a-961e-1c769e48cf70", "93abe397-b96e-4846-bc48-5c242f3a8ce0"], "metadata": {"page_label": "10", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}, "06d9a118-1636-480d-b21d-3ee904356b85": {"node_ids": ["1ab98b7d-a216-4fbb-83f3-87448af1fabd", "0bd9101c-408e-4dfc-b6b5-e00afa197afc", "22052704-67af-4bad-9e7e-691830cbce6e", "85453251-171a-4b92-9525-90761c071881", "fc49b8da-9c07-44e8-8990-3e0258691387", "6ce9a047-d444-4362-9486-37cb9d3aeb7e", "33bb6070-7027-4e5e-b95e-555b18ee5bda"], "metadata": {"page_label": "11", "file_name": "D:/Lab/PKU\u9879\u76ee\u5408\u96c6/Medical-Literature-Benchmark/documents/18493312/18493312.pdf", "file_path": "documents\\18493312\\18493312.pdf", "file_type": "application/pdf", "file_size": 348029, "creation_date": "2024-04-12", "last_modified_date": "2024-04-12"}}}}